Archive for July, 2022

Las Vegas, United States: Straits Researchs latest report on, Preimplantation Genetic Testing Market Global Industry Overview and Forecast 2022-2030, highlights potential, risk factor analyses, and enhanced with strategic and tactical decision-making assistance. The growth and regulatory factors impacting information consumption, the availability of highly dependable items in the market, and the improvement in operating efficiency of Preimplantation Genetic Testing industry players. The Global Preimplantation Genetic Testing Market is expected to reach USD 465.1 million by 2026 at a CAGR of 8.7% during the forecast period of 20192026. Preimplantation Genetic Testing Market Share report covers market trends and development, drivers, capacities, technologies, and the changing dynamics of the Preimplantation Genetic Testing Market.

Competitive Landscape

Some of the prominent players operating in the Preimplantation Genetic Testing market are Illumina, Inc (U.S.), SciGene Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Yikon Genomics (U.S.), Oxford Gene Technology (UK), Rubicon Genomics, Inc. (U.S.), Natera, Inc. (U.S.), Abbott (U.S.), CooperSurgical, Inc (U.S.), and PerkinElmer Inc (U.S.).

Get Free Request Sample Report @ https://straitsresearch.com/report/preimplantation-genetic-testing-market/request-sample

Studies explore the effects of COVID-19 on the upstream, midstream, and downstream sectors of the industry. In addition, this analysis provides extensive market estimations by putting an emphasis on data covering numerous factors that encompass market dynamics such as market drivers, market barriers, market opportunities, market risks, and industry news and trends.

This research also provides a dashboard view of prominent Organization, highlighting their effective marketing tactics, market share and most recent advances in both historical and current settings.

Global Preimplantation Genetic Testing Market: Segmentation

As a result of the Preimplantation Genetic Testing market segmentation, the market is divided into sub-segments based on product type, application, as well as regional and country-level forecasts.

By Procedure Type: Preimplantation Genetic Screening , Preimplantation Genetic DiagnosisBy Technology: Next-Generation Sequencing , Polymerase Chain Reaction , Fluorescence in Situ Hybridization , Comparative Genomic Hybridization , Single-Nucleotide PolymorphismBy Product and Service: Reagents and Consumables , Instruments , Software and ServicesBy Application: Aneuploidy Screening , Structural Chromosomal Abnormalities , Translocations , Deletions , Duplications , Inversions , X-Linked Disorders , HLA Typing , Single Gene Disorder Screening , Gender Identification

The report forecasts revenue growth at all the geographic levels and provides an in-depth analysis of the latest industry trends and development patterns from 2022 to 2030 in each of the segments and sub-segments. Some of the major geographies included in the market are given below:

You may buy this document on Buy Preimplantation Genetic Testing Market Report

Tools and Insights:

Goals of the Study

The Table of Contents and Figures of the Full Report are available for your perusal Preimplantation Genetic Testing Market Report with TOC

Trending Report:

https://www.marketwatch.com/press-release/solar-cable-industry-segmentation-by-top-market-players-general-cable-technologies-corporation-hubersuhner-ag-atkore-international-group-2022-06-17?mod=search_headline

https://www.digitaljournal.com/pr/engine-oil-market-research-2020-industry-growing-with-major-key-player-valvoline-wurth-group-castrol

https://www.digitaljournal.com/pr/energy-blockchain-market-upcoming-trends-segmented-by-type-application-end-user-and-region/

About Us:

StraitsResearch.com is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us:Email: [emailprotected]Address: 825 3rd Avenue, New York, NY, USA, 10022Tel: +1 6464807505, +44 203 318 2846Website: https://straitsresearch.com/

Continue reading here:
Preimplantation Genetic Testing Market Research | Industry Growing with Major Key Player Illumina, Inc (U.S.), SciGene Corporation (U.S.), Thermo...

New Jersey, United States TheDirect-To-Consumer (DTC) Genetic TestingMarket research guides new entrants to obtain precise market data and communicates with customers to know their requirements and preferences. It spots outright business opportunities and helps to bring new products into the market. It identifies opportunities in the marketplace. It aims at doing modifications in the business to make business procedures smooth and make business forward. It helps business players to make sound decision making. Direct-To-Consumer (DTC) Genetic Testing market report helps to reduce business risks and provides ways to deal with upcoming challenges. Market information provided here helps new entrants to take informed decisions making. It emphasizes on major regions of the globe such as Europe, North America, Asia Pacific, Middle East, Africa, and Latin America along with their market size.

Such unique Direct-To-Consumer (DTC) Genetic Testing Market research report offers some extensive strategic plans that help the players to deal with the current market situation and make your position. It helps in strengthening your business position. It offers better understanding of the market and keep perspective to aid one remain ahead in this competitive market. Organizations can gauze and compare their presentation with others in the market on the basis of this prompt market report. This market report offers a clarified picture of the varying market tactics and thereby helps the business organizations gain bigger profits. You get a clear idea about the product launches, trade regulations and expansion of the market place through this market report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=25584

Key Players Mentioned in the Direct-To-Consumer (DTC) Genetic Testing Market Research Report:

23andMe, Ancestry, Karmagenes, Color, Genesis HealthCare, Family Tree DNA, Full Genomes, EasyDNA, Helix, Identigene.

Direct-To-Consumer (DTC) Genetic TestingMarket report consists of important data about the entire market environment of products or services offered by different industry players. It enables industries to know the market scenario of a particular product or service including demand, supply, market structure, pricing structure, and trend analysis. It is of great assistance in the product market development. It further depicts essential data regarding customers, products, competition, and market growth factors. Direct-To-Consumer (DTC) Genetic Testing market research benefits greatly to make the proper decision. Future trends are also revealed for particular products or services to help business players in making the right investment and launching products into the market.

Direct-To-Consumer (DTC) Genetic TestingMarket Segmentation:

Direct-To-Consumer (DTC) Genetic Testing Market, By Test Type

Predictive Testing Carrier Testing Nutrigenomics Testing Others

Direct-To-Consumer (DTC) Genetic Testing Market, By Technology

Single Nucleotide Polymorphism Chips Whole Genome Sequencing Targeted Analysis

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Direct-To-Consumer (DTC) Genetic Testing market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Direct-To-Consumer (DTC) Genetic Testing market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Direct-To-Consumer (DTC) Genetic Testing market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Direct-To-Consumer (DTC) Genetic Testing market by application, it gives a study on the consumption in the Direct-To-Consumer (DTC) Genetic Testing market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Direct-To-Consumer (DTC) Genetic Testing market are profiled in this section. The analysts have provided information about their recent developments in the Direct-To-Consumer (DTC) Genetic Testing market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Direct-To-Consumer (DTC) Genetic Testing market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Direct-To-Consumer (DTC) Genetic Testing market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Direct-To-Consumer (DTC) Genetic Testing market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/direct-to-consumer-dtc-genetic-testing-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read the original post:
Direct-To-Consumer (DTC) Genetic Testing Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This...

Infertility means the inability to conceive even after one year (or longer) of unprotected sexual intercourse. If you are struggling to get pregnant, youre not alone. A large number of people are battling infertility. Various factors such as stress, uterine fibroids, impaired sperm production, blocked fallopian tubes, low ovarian reserve, endometriosis, Polycystic Ovarian Syndrome (PCOS), and premature ovarian failure, can lead to infertility. But, In Vitro fertilization (IVF) treatment at the right age can be helpful for couples.

Age for IVF treatment matters. Couples who opt for the treatment in their early 30s have high chances of successful conception compared to couples in their later 30s because as they get older, the chances will reduce with time.

This revolutionary treatment is helping couples deal with infertility.

Genetic abnormalities are one of the more frequent causes of miscarriage. Preimplantation genetic testing (PGT) can be done in conjunction with IVF to determine in advance whether an embryo is genetically viable, assisting a woman in having a healthy pregnancy. What are you still holding out for? If you have been instructed to begin your IVF treatment immediately, do so.

The preimplantation genetic testing (PGT) on the embryo before it is transferred to the womans uterus will help one to deliver a healthy baby. There are two different kinds, such as PGT-A (preimplantation genetic testing for aneuploidy) and PGT-M (preimplantation genetic testing for monogenetic defects). PGT-A looks for an abnormal number of chromosomes in the embryo. PGT-M is done to know the risk for a specific inherited genetic condition like cystic fibrosis or Tay-Sachs Disease.

Also, read: World IVF Day: 9 things to know if you are opting for IVF treatment

IVF is a highly controlled process wherein only selected good quality eggs are used. And women in their 30s produce a good number of eggs. So, this treatment at an advanced age can raise ones chances of becoming pregnant.

Those who wish to focus on their careers can use IVF techniques if they want a baby in the later stages of life. Eggs or embryos can be cryopreserved for future use too. Also, you can choose a window of time when you want to be pregnant. Thus, it can be easy for you to become pregnant.

Read the rest here:
World IVF Day: 4 benefits of IVF treatment at the right age - Health shots

Research Nester Logo

Key Companies Covered in the Global Metabolic Panel Testing Market Research Report by Research Nester Are SYNLAB International GmbH, Abbott Laboratories, Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Sonic Healthcare Limited, Associated Regional and University Pathologists, Inc., Nova Biomedical Corporation, WerfenLife, S.A., Scion Lab Services, LLC, and other key market players.

New York, July 25, 2022 (GLOBE NEWSWIRE) -- It was noticed that around 2 million people globally pass away from the liver disease each year, with 1 million of those fatalities coming from cirrhosis complications, 1 million from viral hepatitis, and 1 million from hepatocellular carcinoma. Liver cancer is currently the 16th most prevalent cause of death worldwide, while cirrhosis is currently the 11th most common; together, they account for 3.5% of all fatalities worldwide and with a global burden of 1.6 and 2.1%, cirrhosis is one of the top 20 causes of disability-adjusted life years and years of life lost.

Research Nester has published a detailed market report on Global Metabolic Panel Testing Market for the forecast period i.e. 2022 2031 which includes the ongoing industry innovations and recent trends being adopted by the major industry players to achieve their business targets. Apart from that, the inclusive data on market size, growth rate, market revenue share, growth opportunities and challenges for the market players along with worldwide analysis on five major regions North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.

As per the World Health Organization, in 2019, there were 38.2 million children under the age of 5 who were overweight or obese. Since 1975, there has been a more than 3-fold increase in global obesity. The global metabolic panel testing market is estimated to grow with a CAGR of ~7% over the forecast period on the back of rising global chronic disease prevalence namely kidney diseases, diabetes, and liver diseases. It was observed that the bulk of the approximately 422 million individuals with diabetes globally reside in low- and middle-income nations, and diabetes is directly responsible for 1.5 million fatalities annually. Along with these, rising rates of lifestyle-related illnesses, namely, obesity, along with the widespread adoption of unhealthy behaviors including smoking, alcohol consumption, and inactivity are also anticipated to propel significant market expansion during the forecast period.

Story continues

Get a sample copy of the report@ https://www.researchnester.com/sample-request-3994

Furthermore, with the need for more advanced drugs and medical equipment to combat chronic diseases, the majority of the regions across the globe are predicted to significantly invest in research and development activities, which is further estimated to drive the market growth over the ensuing years. For instance, global research and development spending has more than tripled in real terms since 2000, rising from USD 677 billion to USD 2.2 trillion in 2019. In addition to this, the rising expenditure on healthcare across the globe on account of growing public awareness for the importance of early disease detection and treatment is estimated to boost the market growth over the forecast period. As per one of the health expenditure research reports, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).

On the basis of geographical analysis, the global metabolic panel testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region. Out of these, Asia Pacific region is estimated to hold the noteworthy market share over the forecast period on the back of the growing burden of chronic metabolic diseases, and a rising geriatric population in the area who is more prone to acquire chronic metabolic disorders. It is believed that by 2050, one in four people in the Asia Pacific region is estimated to be older than 60, and between 2000 and 2035, type 2 diabetes is predicted to climb by more than 150% in South Asia, aging and accompanying lifestyle changes are the main causes of the rapid increase. In addition to this, the rising healthcare infrastructure and increasing disposable income in the region are estimated to provide lucrative opportunities for market growth over the forecast period.

For more information in the analysis of this report, visit: https://www.researchnester.com/reports/metabolic-panel-testing-market/3994

On the other hand, the market in the North America region is estimated to hold the largest market share over the forecast period owing to the rising number of people opting for regular medical check-ups and increasing expenditure on the healthcare sector on account of the large patient pool in the hospital for on-time diagnostic and treatment of the diseases. As per the Centers for Medicare & Medicaid Services, hospital spending rose 6.4% to USD 1,270.1 billion in 2020, a little faster rate of growth than the 6.3% growth in 2019. Additionally, the increasing consumption of fast food and calorie-dense food, which is leading the region to a higher obesity rate, and increasing medical costs to treat obesity are predicted to drive the market growth over the forecast period. It was observed that, in the years 2015 to 2018, 36.3% of young people between the ages of 2 and 19 ate fast food at least once a day, and in 2019, the estimated yearly medical cost of obesity in the United States was close to USD 173 billion.

The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Get a Sample PDF of Metabolic Panel Testing Market Report@ https://www.researchnester.com/sample-request-3994

The global metabolic panel testing market is segmented by disease into kidney diseases, diabetes, liver diseases, and others. Out of these, the kidney diseases segment is predicted to hold the largest market share over the forecast period owing to the rising incidence of kidney ailments and the quick change in people's lifestyles around the world. It was noticed that, adults in the US are thought to have chronic kidney diseases (CKD) in about 37 million cases, most of which go untreated and around 360 people start receiving dialysis for kidney failure every 24 hours. In addition to this, the patient-friendly healthcare policies in developed and developing regions to treat CKD and end-stage renal diseases (ESRD) are estimated to drive the segment growth over the forecast period. For instance, in the USA, patients with CKD required USD 87.2 billion in treatment in 2019, while those with ESRD required an extra USD 37.3 billion.

Do You Have Any Query Or Specific Requirement? Ask to Our Expert: https://www.researchnester.com/ask-the-analyst/rep-id-3994

Further, the global metabolic panel testing market is segmented by end user into point-of-care centers and laboratories. Out of these, the laboratories segment is estimated to gain significant market share over the forecast period owing to the high spending by patients to receive test results from reputable laboratories and their association with blood banks, hospitals, and specialist diagnostic centers. It is believed that by 2024, the medical and diagnostic laboratories in the United States are estimated to generate around USD 54 billion in revenue. In addition to this, the release of precise and cutting-edge devices including companion diagnostics, biochips, microarrays, and other technological advancements in the laboratories segment are estimated to drive the segment growth over the forecast period.

The global metabolic panel testing market is also segmented on the basis of test type.

Global Metabolic Panel Testing Market, Segmentation by Test Type

Electrolytes

Proteins

Kidney Tests

Glucose

Liver Functional Tests

Others

Some of the prominent key players and their company profiling mentioned in the global metabolic panel testing market research report include SYNLAB International GmbH, Abbott Laboratories, Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Sonic Healthcare Limited, Associated Regional and University Pathologists, Inc., Nova Biomedical Corporation, WerfenLife, S.A., Scion Lab Services, LLC, and other key market players. The profiling enfolds growth opportunities, challenges, and market trends prevalent for the growth of the market.

For more insights on the market share of various regions: https://www.researchnester.com/sample-request-3994

Explore Our Recent Related Reports:

Hepatitis C Virus (HCV) testing Market By Test Kits (Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test, Hepatitis C RNA Qualitative Test, Hepatitis C RIBA, Hepatitis C Genotype, Viral Load); By End-User (Diagnostic Centers, Hospitals, Blood donation centers) - Global Demand Analysis & Opportunity Outlook 2027Point of Care Genetic Testing Market Segmentation By Technology (Polymerase Chain Reaction, Hybridization, Chips and Microarrays); By End Use (Decentralized Labs, Hospitals, Assisted Living Healthcare Facilities) - Global Demand Analysis & Opportunity Outlook 2027Global Hemostasis Testing Systems Market By Application (Acquired Bleeding Disorders, Congenital Bleeding Disorders); By Product (Laboratory systems, Consumables, Point-of-care testing systems); By End-User (Hospitals, Clinics, Academic Institutions, Diagnostic Laboratories) - Global Demand Analysis & Opportunity Outlook 2027Cellular Health Screening/Health Testing Market Segmentation By Test Type (Telomere Test, Oxidative Stress Test, Inflammation Test, Heavy Metal Test, Single Test Panel & Multi Test Panel); By Sample Type (Blood Samples, Body Fluids & Other Samples); By Collection Site (Home, Office & Other Sites) - Global Demand Analysis & Opportunity Outlook 2027Non-Invasive Prenatal Testing (NIPT) Market Segmentation By Product Type (Consumables, Disposables, Assay Kits & Reagents, Next-Generation Sequencing System, PCR Instruments, Ultrasound Devices, Microarrays and Others); By Test Type (MaterniT21 PLUS, NIFTY, Harmony test, Prena Test, Panorama Test, Verifi and others); By Method; By Application (Microdeletion Detection, Trisomy Detection & Others); By End User (Diagnostic Laboratories & Hospitals) - Demand Analysis & Opportunity Outlook 2027

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:AJ DanielEmail:info@researchnester.comU.S. Phone: +1 646 586 9123U.K. Phone: +44 203 608 5919

For More Update Follow: -LinkedIn|Twitter|Facebook|Xing

More here:
Global Metabolic Panel Testing Market to Grow with a CAGR of ~7% During 2022-2031; Market Growth to be Propelled by Increasing Prevalence of Chronic...

Buying companies with proven products or services that are operating in thriving industries is a must for growth investors. Genetic testing is one such industry. There has been an increase awareness and interest in testing for genetic disorders and cancers. That's why Allied Market Research predicts that the genetic testing industry will grow at a 10.1% annual rate, reaching $21.3 billion by 2027.

With a $1.9 billion market capitalization, Veracyte (VCYT 0.53%) is a lesser-known name in the industry. The company leverages genomic technology to help physicians more confidently diagnose and treat chronic conditions. The thought is that this will lead to better treatment outcomes for patients. The company's tests are used to diagnose and guide treatment decisions for conditions like lung cancer, prostate and bladder cancers, thyroid cancer, breast cancer, and colon cancer.

Here are three reasons why growth investors may want to familiarize themselves with the medical diagnostic company and consider buying its shares.

Veracyte reported $67.8 million in revenue for the first quarter ended March 31, up 84.7% from the year-ago period. This was much higher than the $62 million that analysts were expecting in the quarter. So how did the genetic test maker exceed analysts' predictions for the 10th quarter out of the last 10 quarters?

Testing revenue of $56 million in the first quarter accounted for the vast majority of Veracyte's total, and it was up 69.2% year over year. The deferral of diagnostic tests in past quarters acted as a coiled spring for the company in the first quarter. This explains how its test volumes soared 61% higher over the year-ago period to 23,245 during the quarter.

Veracyte's biopharmaceutical and other revenue surged to $8.8 million in the first quarter. This was much higher than the $0.6 million in revenue recognized for the first quarter of the prior year, which was due to contributions from the acquisition of the immuno-oncology company HalioDx last August. Meanwhile, product volume for Veracyte's ProSigna breast cancer tests dropped 2.6% year-over-year to $3 million for the first quarter. Minimal test volume growth was more than neutralized by a 5% currency headwind during the quarter.

As pent-up demand for its products wanes, Veracyte expects that revenue growth will significantly moderate in the remaining three quarters of the year. The pent-up demand stems from less diagnostic tests being performed in the early days of the COVID-19 pandemic. Now that deferred diagnostic tests are finally being completed, there will be less of a demand going forward.

Even so, the company is forecasting $270 million in midpoint revenue for the year. This equates to a 23% growth rate over 2021. And analysts believe that growth will remain just as strong in 2023 at 19%.

Image source: Getty Images.

Another important reason why analysts are optimistic about Veracyte's future prospects has to do with the company's rock-solid balance sheet. Veracyte boasts a $163.6 million cash balance against $1.1 million long-term debt. Thus, the company is sitting on a net cash balance of $162.5 million, which is equivalent to over 8% of its market capitalization. This should give Veracyte the funds necessary to execute bolt-on acquisitions and future product launches.

Since Veracyte is more focused on revenue growth than profitability, the price-to-earnings ratio would be of no use in valuing the stock. That's why I would argue that the price-to-sales (P/S) ratio is more appropriate for Veracyte -- and currently it is trading at a multiple of seven. Considering that Veracyte is growing at a rate of around 20% annually, this is arguably a solid entry point for growth investors.

Kody Kester has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Veracyte. The Motley Fool has a disclosure policy.

Read more from the original source:
3 Reasons to Buy This Sizzling Growth Stock - The Motley Fool

A person arrives to receive a monkeypox vaccination at the Northwell Health Immediate Care Center at Fire Island-Cherry Grove, in New York, US, July 15, 2022. [Photo/Agencies]

The World Health Organization has declared that the monkeypox outbreak in multiple countries is now a public health emergency of international concern, the highest level of alert it can sound.

At a time when a similar alert issued against the COVID-19 pandemic remains in place, identifying monkeypox as another public health emergency of international concern increase the global health challenge.

That WHO upgraded the outbreak from a pandemic to a public health emergency of international concern in just a month goes to show how fast the situation has changed. Altogether 16,000 monkeypox cases have been reported in 75 countries and regions around the world, with the number of confirmed infections increasing by 77 percent from late June to early July. Monkeypox used to be endemic to Africa, but now outbreaks have been reported from many countries and regions, including in Europe, the Americas and Asia.

The WHO has announced public health emergencies of international concern seven times in history. Aside from monkeypox, it has done so for influenza A(H1N1) virus in 2009, the wild poliovirus in 2014, the Ebola virus in West Africa in 2014, the Zika virus in Brazil in 2016, the Ebola virus in the Democratic Republic of the Congo in 2018-20 and the COVID-19 pandemic in 2020. The world is thus saddled with a new challenge even as it grapples with COVID-19.

Considering that no monkeypox cases have been reported on the Chinese mainland, China's current efforts should focus on preventing imported cases from abroad. In fact, the General Administration of Customs issued a notice as early as May 30, requiring all ports across the country to continue with measures to prevent the import of "multiple diseases".

China has established a variety of genetic testing techniques for the early diagnosis of monkeypox.

The National Health Commission has also issued a technical guide on monkeypox prevention and control, explicitly requiring its early detection, reporting, diagnosis, investigation and treatment. It has also raised specific requirements for the standardization of monkeypox epidemiological investigation, contact determination and management, laboratory testing and other work.

There is no need for the public to panic at this stage. The risk of infection can be effectively lowered by reducing gatherings, wearing masks, washing hands frequently and avoiding contact with wild animals.

- BEIJING NEWS

The rest is here:
Monkeypox, yet another health emergency for world to cope with - China Daily

Novel Automated Design Enables Comfortable Home and Clinic Based Blood Collection with Robotic High-Throughput Processing

WALTHAM, Mass.--(BUSINESS WIRE)-- Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending VERIstic Collection Device focused on small volume blood collection. The VERIstic is ideal for use in at-home and clinician-assisted collection methods and is a highly efficient, high-throughput replacement for antibody, hormone and protein detection, sexually transmitted infections (STIs), dried blood spot (DBS) cards, genetic testing, clinical trials, and other applications enabled by a simple finger prick collection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005248/en/

The VERIstic is the first of its kind collection device combining tried-and-true capillary blood collection with an integrated, automation-ready cap to save time, money, and hassles in a hands-free workflow when the sample reaches the laboratory. For patients and clinicians, the collection is rapid, simple, and comfortable. Once the finger is pricked with a lancet, 50 L of blood is instantly wicked up the unique and patent-pending 3-sided capillary tube. The tube is screwed into its matching transport tube for shipment to the laboratory. When it reaches the laboratory, 96 samples can be accessioned in seconds through 2D barcodes located on the transport tube bottom followed by robotic decapping of the samples, rapid elution of the sample, and automated liquid handling technologies. With gentle agitation, blood elutes from the capillary tube and is immediately ready for processing while lab technicians are free to focus their attention elsewhere. (Photo: Business Wire)

Were very excited to bring this truly unique and simple innovation to the blood collection market, said Cheri Walker, PhD, President and CEO of Rhinostics. Finally, patients and clinicians can be assured of comfortable metered blood collection, where the clear capillary allows the collector to monitor collection and laboratories gain consistent blood collection combined with cost and time-saving efficiencies during processing through automated decapping and robotic sample processing.

This first of its kind collection device combines tried-and-true capillary blood collection with an integrated, automation-ready cap to save time, money, and hassles in a hands-free workflow when the sample reaches the laboratory. For patients and clinicians, the collection is rapid, simple, and comfortable. Once the finger is pricked with a lancet, 50 L of blood is instantly wicked up the unique and patent-pending 3-sided capillary tube. The tube is screwed into its matching transport tube for shipment to the laboratory. When it reaches the laboratory, 96 samples can be accessioned in seconds through 2D barcodes located on the transport tube bottom followed by robotic decapping of the samples, rapid elution of the sample, and automated liquid handling technologies. With gentle agitation, blood elutes from the capillary tube and is immediately ready for processing while lab technicians are free to focus their attention elsewhere. The VERIstic enables efficient, hands-free and low labor workflows.

VERIstic is suited for a range of applications including other small volume body fluids, blood monitoring, wound care, clinical trials, and a number of home- or clinic-based sample collection needs. Rhinostics will mark the global debut of this device at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo to be held July 26-28 in Chicago, IL.

About Rhinostics

Rhinostics is at the forefront of revolutionizing sample collection. As a spin-out company from Harvard University and Wyss Institute, we are taking a radical new approach to sample collection device design and function. We recognize that many automated microplate-based workflows are encumbered by manual steps at the workflows beginning, and aim to develop and commercialize elegant, automated collection devices to break through these bottlenecks. Using our advanced collection device technologies such as the RHINOstic Automated Swab, test kit manufacturers can empower comfortable yet high-end patient experiences with abundant and clean sample yields for tests from lateral flow to microfluidics; all while boosting profits and differentiating their brand. Test processing laboratories conducting sensitive assays from traditional PCR to LAMP or antigen testing and more gain 10x sample throughput compared to manual workflows for cost-effective and robust assay performance even when working with difficult samples; with labor reductions of 80+%, even during times of surging demand. Rhinostics aids testing workflows during the COVID-19 pandemic and beyond in areas like respiratory disease, genomics, STDs, forensic and much more. Rhinostics continues to innovate, launching the novel VERIstic Collection Device and with a development pipeline of improved sample collection devices that are purpose-built for their application combined with automation enablement. Rhinostics products are registered as Class I exempt medical devices with the U.S. FDA and may be used for clinical collection upon CLIA validation. In 2022, Rhinostics received a Bronze Edison Award in the COVID-19 Innovations, Testing Solutions category for the RHINOstic Automated Swab. To learn more, visit https://www.rhinostics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005248/en/

Originally posted here:
Rhinostics Launches the VERIstic to Redefine Small Volume Blood Collection - BioSpace

Get Sample ReportBuy Complete Report

New Jersey, USA,-The Global Direct-To-Consumer (DTC) Genetic Testing Market study provides a comprehensive examination of the market throughout the projection period. The study covers a variety of sections as well as an analysis of the events and factors that are likely to play a significant role in the future. These elements, known as market dynamics, include the drivers, restrictions, options, and difficulties that shape the overall image of those components. The markets intrinsic components are the drivers and restraints, while the extrinsic components are the alternatives and difficulties. Throughout the forecast period, the Global Direct-To-Consumer (DTC) Genetic Testing Market report provides an insight on the markets performance in terms of revenue.

This research provides an all-encompassing assessment of the global Direct-To-Consumer (DTC) Genetic Testing market. The market estimations presented in the report are based on extensive secondary research, primary interviews, and in-house expert evaluations. These market estimations were developed by examining the impact of various social, political, and financial factors, as well as current market dynamics, on the Global Direct-To-Consumer (DTC) Genetic Testing Market.

Click the link to get a Sample Copy of the Report:https://www.marketresearchintellect.com/download-sample/?rid=248561

To ensure that the specific detailing of the Global Direct-To-Consumer (DTC) Genetic Testing markets footprint and sales demographics are captured with precision, an in-depth analysis of several regions is carried out, allowing the user to make the most of the data.

Market Segmentation:

Key Players:

Segment by Types:

Segment by Applications:

Get | Discount On The Purchase Of This Report @https://www.marketresearchintellect.com/ask-for-discount/?rid=248561

Regions Are covered By Direct-To-Consumer (DTC) Genetic Testing Market Report 2022 To 2028

For a comprehensive understanding of market dynamics, the global Direct-To-Consumer (DTC) Genetic Testing market is analyzed across key geographies namely: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, and Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa). Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Direct-To-Consumer (DTC) Genetic Testing Market Report Scope:

For More Information or Query or Customization Before Buying, Visit:https://www.marketresearchintellect.com/product/global-direct-to-consumer-dtc-genetic-testing-market-size-and-forecast/

Industry Overview:The first section of the research study covers an overview of the global Direct-To-Consumer (DTC) Genetic Testing Market,market status and prospects,and product range. In addition,it provides highlights of the major segments of the global Direct-To-Consumer (DTC) Genetic Testing Market,i.e. region, type and application segments.

Competitive Analysis:This report illuminates important mergers and acquisitions,business expansion,product or service differences,market concentration,competitive status of the global Direct-To-Consumer (DTC) Genetic Testing Market, and market size by player.

Company Profiles and Key Data:This section covers companies profiling the major players in the global Direct-To-Consumer (DTC) Genetic Testing Market based on the aforementioned revenue,products,business and other factors.

Market size by type and application:In addition to providing in-depth analysis of the global Direct-To-Consumer (DTC) Genetic Testing Market size by type and application,this section provides research on top end users or consumers and potential applications.

Market Dynamics:This report covers the drivers, trends and opportunities of the global Direct-To-Consumer (DTC) Genetic Testing Market. This section also includes Porters analysis of five forces.

Findings and Conclusions:It provides strong recommendations for new as well as established players for securing a position of strength in the global Direct-To-Consumer (DTC) Genetic Testing Market.

Benefits of PurchasingCancer immunotherapyMarket Reports:

About Us:Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:Mr. Steven FernandesMarket Research IntellectNew Jersey (USA)Tel: +1-650-781-4080Website: https://www.marketresearchintellect.com/

More here:
Direct-To-Consumer (DTC) Genetic Testing Market Size, Forecast And Trend Analysis To 2028 This Is Ardee - This Is Ardee

Japan is a leader in developing drugs and medical devices that are used worldwide. What contributions has Precision System Science (PSS) made to the medical field?

I learned the business from a domestic perspective, but I have a close relationship with an international partner who worked in Abbott before and since then, I have established connections with Roche and Thermo Fisher. As an SME, we have learned that big companies lack the inspiration to produce compact and easy-to-use products. PSS has received praise from larger companies for providing compact technology quickly and efficiently with highly accurate and precise diagnostic results. We will continue looking into what we can do as an SME and doing what major companies dont have the inclination to do themselves.

We have developed automated technologies that allow sample-to-result: nucleic acid extraction (DNA or RNA etc) to amplification and detection, and these can be used to conduct PCR testing quickly in just two hours. The equipment is small yet high-tech and we believe it is one of a kind. Our design concept is to develop devices that are small, compact, efficient, easy to use, and highly accurate and precise diagnostic results, therefore with features that large companies usually dont provide.

Magnetic filtration technology, or Magtration, is the core of our business. It uses magnetic beads and the system we have developed, and we realised that Magtration technology is very efficient in terms of sample preparation (nucleic acid extraction) of open systems in the field of molecular diagnostic and that is how the technology was developed. This is the very first automated sample preparation system that succeeded and thanks to this, we have received OEM orders from Roche and QIAGEN and have produced about 40,000 units so far.

Healthcare systems in many countries have been severely affected by the COVID-19 pandemic. As you mentioned, you have developed a fully automated PCR testing system that reduces testing time from six to two hours and removes the possibility of human error. How can such devices help mitigate the impact of future epidemics or pandemics, especially in countries with weak healthcare systems, such as developing and low-income nations?

PCR testing offers a high possibility of detection right after infection compared to protein-based antigen testing. If middle and low-income countries were to introduce a system to detect future infectious diseases, then PCR testing would be advantageous, and we would promote its adoption. About twenty years ago, we collaborated with the Japanese Red Cross Society to reduce serum hepatitis incidence after transfusions, and in addition to working with Roche, we were involved in preventing not only serum hepatitis, but also the spread of HIV and other diseases transmitted by blood, including through transfusions, by developing a device of sample preparation that could confirm contaminated blood combining a sample pooling method for multiple detection. Thanks to that, we have been able to significantly decrease the spread of hepatitis and HIV transmissible by blood.

In addition to our Magtration technology, we are developing a print-made cartridge. The systems used by major companies are becoming very complex and by providing this cartridge pre-filled with reagent and allowing any country in the world to use it new contaminants can be detected. We have also developed a soak stick kit: a saliva sample is taken, and the vial doesnt need to be filled with reagent by the testing machinery if used in combination with the cartridge. The saliva kit is combined with an inactive virus infection like COVID-19 solution, meaning the person conducting the test wont be infected.

8 years ago, we established a partnership with French company ELITech, who wanted to sell their PCR reagent with their machinery. The OEM product is sold as ELITe InGenius, but now we are developing a version called BeGenius which we have announced publicly. We have high expectations for providing our products to ELITech, in addition to evolving with them and gaining a stronger market presence.

At the same time, there are many challenges. One of them is that it takes two hours for us to get the fully automated results of the PCR test with highly accurate and precise diagnostic results, however we want to reduce this to less than an hour with the same quality of diagnostic results. To reach this goal, we will increase the speed of hardware movement, while also upgrading the software to be more efficient. We are doing our best to evolve this as a business, as well as contribute to society, by providing an automated PCR testing device that takes less time, and which would be particularly convenient for locations such as airports. It is also very compact, so placing it in these locations wouldnt be difficult.

The machine itself scans barcodes placed on the samples, however, to ensure that there are no mistakes, handwritten labels that the machine can recognise are also used. Since the process is automated, the samples arent at risk of being contaminated during testing. The testing kit is also packaged with the machine. It is still a medical device, so a person must be trained to operate it, but it is easy to use, therefore making mistakes less commonplace. Originally, our machines were used for organ transplant testing, but with the rise of infectious diseases, we decided to incorporate this type of testing too.

We recently completed our work with Kyoto University, with whom we collaborated on the development of a high-precision pool-based mass screening system for SARS-CoV-2 (the COVID-19) detection using a fully automated genetic testing device. In the validation study, a total of 2,448 saliva and swab samples were tested, and the results showed a sensitivity of 97.1% and a specificity of 99.9%, demonstrating the high accuracy of this system.

For example, in a context where multiple people are tested at the same time, such as an airport, and in which a small minority of people test positive, while the majority are negative, eight samples are tested simultaneously, allowing for immediate detection of the positive samples.

PSS Matsudo Head Office

geneLEAD VIII

PSS Shinjuku Laboratory

NPS & Odate Reagent Center

You have a highly diversified product line-up. What product or products are you currently focusing on?

Our business model has changed in response to the COVID-19 pandemic. We didnt produce reagents for PCR before, until we partnered with a European company providing them with the pre-packaged reagents. We have always been a machinery developer and have constantly asked ourselves what reagents should be used with our machinery for testing.

Your platform Bio System is an open system to provide solutions in a variety of fields, including oncology and stem cell research. Can you tell us more about it?

The Bio System is planned to extract very fine particles within the body: by extracting them using Magtration technology or the cartridge reagent, we can apply the procedure in many fields, including disease detection. Our strengths are in sample preparation and conducting the diagnosis. To take advantage of our this strengths by establishing a mass production supply chain of our Prefilled Reagent Cartridge for Magnetic Bead Based Nucleic Acid Extractions, we are constructing the second plant of the Odate Reagent Center (targeted to start operation in the first half of 2022).

The reagent manufacturing capacity will be significantly increased from approximately 6 million tests/year to approximately 36 million tests/year to meet various genetic testing needs including PCR testing.

You have an in-house R&D department in Ichikawa, in Chiba prefecture, where you are tirelessly developing new products. What is the centres focus?

Recently, our development has moved in the direction of finding applications for the research and technology that we have accumulated over time. Unlike other companies, which use 96 microplates as a standard, we adopt a unique approach where we focus on each specific sample. Combined with our technologies, this approach allows us to create new approaches, such as detecting diseases that were previously difficult to diagnose.

How will you achieve clinical diagnosis using genes? Are you looking for partners to create new products for this specific market?

We now work with academic institutions, both internationally and domestically, whereas beforehand we were only working with other medical companies. We usually do as much as we can by ourselves, as we want to establish our one-of-a-kind technologies and devices.

Recently, you opened an Inspection center in Shinjuku, Tokyo. What is a purpose of the Establishment of "PSS Shinjuku Laboratory" which have opened last October as a Sanitary Inspection Center?

Ons and academia. In order to achieve corporate citizenship, we will also conduct PCR testing for COVID-19 infections from corporate entities and plan to establish a business cooperation group with the aim of "establishing a system where anyone can receive fast & accurate PCR tests anytime, anywhere" by deploying such facilities not only in Japan but also on a global scale.

On account of its ageing population, Japan is facing the need to focus more on healthcare prevention, rather than treatment. How are you catering to this trend?

Alzheimers, for example, is very difficult to treat, more so than cancer, and many pharmaceutical companies have invested trillions of yen to develop a drug to treat it, but to no avail. What is important is that if you can detect Alzheimers 10 or 20 years before its onset, then you are in a better position to treat it and potentially avoid suffering being caused by the disease. The same applies to cancer. Early detection is very important, and we are trying to utilise our technologies to create ways to detect these diseases.

You are present in Germany and the United States. Could you tell us why you chose these locations?

The reason we have businesses there is that we have partners in those countries. Japan is behind when it comes to understanding the need for PCR technology. Instead, there is a higher demand in the American and European markets, and we are working as an OEM provider with our partners in those locations.

What is your strategy to further expand internationally?

We have received many offers to be purchased by larger companies, but we have declined them because we want the freedom to develop what we like. Currently, we have distribution partners in the United States, Spain, Italy, France, Belgium, and Sweden, among others. In our work with overseas companies, we have been providing OEM products, but we are aiming to develop a PSS brand and sell our products directly. For now, we believe our best option is to have partnerships with agents who understand our products well and develop good distribution networks.

Imagine we come back in four years time for PSSs 40th anniversary. What goals would you like to have achieved by then?

We want to enter niche fields that havent been entered yet. For example, the area of disease detection that we discussed earlier hasnt been dealt with successfully. We want to provide technology that caters to and provides solutions for such frontier areas.

Read the rest here:
PSS: Providing quick and effective solutions - The Worldfolio

KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc. today announces that Atlas Genomics, Prevencios performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencios HART tests. The coverage includes HART CVE, the only blood test available for assessing a patients one-year risk for a heart attack, stroke, or cardiac death, and HART CADhs for assessing a patients risk for significant blockage of a heart artery.

In conjunction with researchers and clinicians at Massachusetts General Hospital, HART test data has been presented at leading cardiology scientific sessions and has been published in peer-review journals. The HART tests are significantly more accurate than single protein blood tests, standard-of-care stress tests, clinical risk scores, and genetic tests. The HART tests are also accurate in patients with diabetes and chronic kidney disease, conditions that often confound other blood-based tests or have contraindications for dye-based imaging, including Cardiac Computed Tomography Angiograms (CCTA).

Prevencio is grateful for our laboratory partnership with Atlas Genomics and is excited to collaborate with Alivio Health to provide 125,000 Americans with increased access to our precision care HART tests, said Rhonda Rhyne, Prevencios Chief Executive Officer. Through Alivio Health, we intend to expand awareness, access, reimbursement, and utilization of HART cardiac tests for the benefit of patients. Our mission is preventing the preventable by providing patients, clinicians, and employers with personalized tests that are more accurate, safer, and more affordable for preventing, identifying, treating, and monitoring the tens of millions of patients with cardiac issues.

Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association, the U.S. spends approximately $316 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, more than 40% of the U.S. adult population is projected to have cardiovascular disease. For additional information, visit Prevencio, Inc.

About Prevencio, Inc.: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multiple Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic tests, and clinical risk scores. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.

About Atlas Genomics: Atlas Genomics is a high-complexity, CLIA- and CAP-accredited molecular diagnostic laboratory headquartered in Seattle, Washington. Atlas has specialized in molecular and genetic testing since its inception in 2014, offering womens health, COVID 19, cardiovascular testing (via novel Prevencio HART tests), stem cell analysis, cytogenetics, and research testing in support of biotechnology companies nationwide. Atlas primary technologies include next generation sequencing (NGS), RT-PCR, and proteomics.

About Alivio Health: Alivio Health is a national genetic benefit solutions company committed to providing access to a comprehensive suite of molecular and advanced diagnostics enabling actionable insights for patients and their physicians. The constant and rapid expansion of genetic services has left laboratories and payers of healthcare incessantly navigating challenges around medical policy, coverage, and reimbursement. Alivio Health, through its comprehensive nationwide network of molecular and advanced testing laboratories, is facilitating access to the right test at the right time for employers and their employees. For additional information, visit Alivio Health.

Forward-Looking (Safe Harbor) Statement:

Prevencio cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the expected benefits of the partnership with Alivio Health, including the availability and expected use of Prevencios tests through the Alivio Healths network, and any potential for increased use of HART tests. The Companies do not undertake to update disclosures contained in this press release.

See the original post:
Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics - Business Wire

Global Stem Cell ManufacturingMarket Is Expected To Reach USD 21.71 Billion By 2029 At A CAGR Of 9.1 percent.

Maximize Market Research has published a report on theGlobal Stem Cell Manufacturing Marketthat provides a detailed analysis for the forecast period of 2022 to 2029.

Global Stem Cell ManufacturingMarket Scope:

The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industrys history and present situation, as well as expected market size and trends. The research investigates all industry categories, with an emphasis on key companies such as market leaders, followers, and new entrants. The paper includes a full PESTLE analysis for each country. A thorough picture of the competitive landscape of major competitors in theGlobal Stem Cell Manufacturingmarket by goods and services, revenue, financial situation, portfolio, growth plans, and geographical presence makes the study an investors guide.

Request Free Sample:@https://www.maximizemarketresearch.com/request-sample/73762

Global Stem Cell Manufacturing Market Overview:

Observing stem cells evolve into cells in bones, the circulatory system, nerve cells, and other organs of the body may help scientists understand how illnesses and disorders occur. Stem cells can be programmed to generate particular cells that can be utilized in humans to grow and mend tissues that have been damaged or harmed by sickness. Stem cell therapy may assist people with spinal cord injuries, metabolic disorders, Parkinsons disease, amyotrophic lateral sclerosis, Alzheimers disease, cardiovascular disorders, brain hemorrhage, burns, malignancy, and rheumatoid arthritis. Stem cells can be used to create new tissue for transplant and genetic engineering. Doctors are always learning more about stem cells and how they might be used in transplant and cellular therapies.

Global Stem Cell ManufacturingMarketDynamics:

Stem cells are crucial in illness treatment and specialized research initiatives such as customized therapy and genetic testing. As public and commercial stakeholders throughout the world become more aware of stem cells therapeutic potential and the scarcity of therapeutic approaches for rare illnesses, they are increasingly focusing on the development of stem cell-based technology.

Specialized procedures are required for stem cell separation, refinement, and storage (such as expansion, differentiation, cell culture media preparation, and cryopreservation). Additionally, the production scale-up of stem cell lines and associated items is frequently accompanied by major technological challenges that impede the whole production process and result in large operational expenses. As a result, stem cell products are frequently more expensive than pharmaceutical medications and biopharmaceuticals.

Additionally, the growing popularity of tailored medications is driving the market growth. Scientists are researching novel procurement strategies that can be used to manufacture tailored medications. For example, iPSC treatments are created by taking a little amount of a patients plasma or skin cells and reprogramming them to make new cells and tissue for transplant. As a result, future tailored treatments can be produced using these cells.

Global Stem Cell ManufacturingMarketRegional Insights:

North America (particularly the United States) held the largest market share in 2021, owing to factors such as the availability of significant contenders active in creating stem cell treatments, enhanced medical facilities, significant R&D financial backing available, and favorable initiatives from healthcare organizations, as well as robust reimbursement. Because of government initiatives and serious scientific activity in the country, the United States leads the continentsGlobal Stem Cell Manufacturingmarket.

Healthcare organizations are promoting cellular therapies for rising ailments. Due to higher advancement of stem cell-based treatments, federal actions for creating regenerative medications, the creation of multiple stem cell banks, and the continents increasing clinical studies for genetic manipulation and medical technology, the APACGlobal Stem Cell Manufacturingmarket is expected to grow at the fastest rate during the forecast period.

Global Stem Cell ManufacturingMarketSegmentation:

By Product:

By Application:

By Technology:

By Therapy:

Global Stem Cell ManufacturingMarket Key Competitors:

To Get A Copy Of The Sample oftheGlobal Stem Cell ManufacturingMarket, Click Here:@https://www.maximizemarketresearch.com/market-report/global-stem-cell-manufacturing-market/73762/

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Continue reading here:
Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal

ICYMI: Amazon Prime Day is coming to an end tonight and truth be told, the sales appear to be gifts that keep on giving. One of our favorite skin-care tools is having a major discount across all of its devices and treatments. Yep, you guessed it, it's NuFace.

If you're unfamiliar with the brand and the magic it can do, let us school you quickly. NuFace devices use microcurrent technology that the brand calls "fitness for your face." In the same way that consistently hitting weights and cardio whips our body's muscles into shape, the metal nodes on the head of the tools send electrical currents through the various layers of facial skin, down to the muscles, to basically give them a workout.

Into it? Well, lucky for you NuFace products will be available at a discount throughout this two-day epic sale. Starting right now through July 13, you can snag devices, boosters, and activators for up to 36 percent off. The sale includes top-selling products like the Trinity, NuBody, Fix, and more.

So what are you waiting for? This luxury tool rarely goes on sale so get to shopping because these discounts end later on when Prime Day closes its virtual doors.

NuFace Trinity Starter Kit

NuFace Trinity Complete Kit

Both the Trinity Starter Kit and Complete Kit are essentially the same thing, but the complete kit comes with some additional attachments. Both kits feature a NuFace device and a gel primer to apply prior in order to activate the current. However, the Complete Kit holds a dual wand that targets specific areas like around the lips and eyes and a LED light attachment that helps reduce the appearance of fine lines and wrinkles.

If you're not into breaking the $200 mark, consider the Mini Starter Kit it holds the same device and gel primer, just in a smaller (more portable!) version that achieves the same results.

The NuBody features those same nodes on the head as the Trinity but in a handheld body version that utilizes four nodes. With four electrical currents, this device sends waves through the skin down to the muscles to help sculpt and tone the body. Plus, you get a 10-ounce gel primer to ensure the device glides smoothly and evenly.

See the rest here:
NuFace Is Having a Major Sale During Amazon Prime Day 2022 See Deals on Trinity, NuBody, and More - Allure

In molecular biologist David Sinclair's lab at Harvard Medical School, old mice are growing young again.

Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset aging cells in mice to earlier versions of themselves. In his team's first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offspring's.

"It's a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age," said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

"If we reverse aging, these diseases should not happen. We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimer's in your 90s." Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

"This is the world that is coming. It's literally a question of when and for most of us, it's going to happen in our lifetimes," Sinclair told the audience.

"His research shows you can change aging to make lives younger for longer. Now he wants to change the world and make aging a disease," said Whitney Casey, an investor who is partnering with Sinclair to create a do-it-yourself biological age test.

While modern medicine addresses sickness, it doesn't address the underlying cause, "which for most diseases, is aging itself," Sinclair said. "We know that when we reverse the age of an organ like the brain in a mouse, the diseases of aging then go away. Memory comes back; there is no more dementia.

"I believe that in the future, delaying and reversing aging will be the best way to treat the diseases that plague most of us."

A reset button

In Sinclair's lab, two mice sit side by side. One is the picture of youth, the other gray and feeble. Yet they are brother and sister, born from the same litter -- only one has been genetically altered to age faster.

If that could be done, Sinclair asked his team, could the reverse be accomplished as well? Japanese biomedical researcher Dr. Shinya Yamanaka had already reprogrammed human adult skin cells to behave like embryonic or pluripotent stem cells, capable of developing into any cell in the body. The 2007 discovery won the scientist a Nobel Prize, and his "induced pluripotent stem cells," soon became known as "Yamanaka factors."

However, adult cells fully switched back to stem cells via Yamanaka factors lose their identity. They forget they are blood, heart and skin cells, making them perfect for rebirth as "cell du jour," but lousy at rejuvenation. You don't want Brad Pitt in "The Curious Case of Benjamin Button" to become a baby all at once; you want him to age backward while still remembering who he is.

Labs around the world jumped on the problem. A study published in 2016 by researchers at the Salk Institute for Biological Studies in La Jolla, California, showed signs of aging could be expunged in genetically aged mice, exposed for a short time to four main Yamanaka factors, without erasing the cells' identity.

But there was a downside in all this research: In certain situations, the altered mice developed cancerous tumors.

Looking for a safer alternative, Sinclair lab geneticist Yuancheng Lu chose three of the four factors and genetically added them to a harmless virus. The virus was designed to deliver the rejuvenating Yamanaka factors to damaged retinal ganglion cells at the back of an aged mouse's eye. After injecting the virus into the eye, the pluripotent genes were then switched on by feeding the mouse an antibiotic.

"The antibiotic is just a tool. It could be any chemical really, just a way to be sure the three genes are switched on," Sinclair said. "Normally they are only on in very young developing embryos and then turn off as we age."

Amazingly, damaged neurons in the eyes of mice injected with the three cells rejuvenated, even growing new axons, or projections from the eye into the brain. Since that original study, Sinclair said his lab has reversed aging in the muscles and brains of mice and is now working on rejuvenating a mouse's entire body.

"Somehow the cells know the body can reset itself, and they still know which genes should be on when they were young," Sinclair said. "We think we're tapping into an ancient regeneration system that some animals use -- when you cut the limb off a salamander, it regrows the limb. The tail of a fish will grow back; a finger of a mouse will grow back."

That discovery indicates there is a "backup copy" of youthfulness information stored in the body, he added.

"I call it the information theory of aging," he said. "It's a loss of information that drives aging cells to forget how to function, to forget what type of cell they are. And now we can tap into a reset switch that restores the cell's ability to read the genome correctly again, as if it was young."

While the changes have lasted for months in mice, renewed cells don't freeze in time and never age (like, say, vampires or superheroes), Sinclair said. "It's as permanent as aging is. It's a reset, and then we see the mice age out again, so then we just repeat the process.

"We believe we have found the master control switch, a way to rewind the clock," he added. "The body will then wake up, remember how to behave, remember how to regenerate and will be young again, even if you're already old and have an illness."

Science already knows how to slow human aging

Studies on whether the genetic intervention that revitalized mice will do the same for people are in early stages, Sinclair said. It will be years before human trials are finished, analyzed and, if safe and successful, scaled to the mass needed for a federal stamp of approval.

While we wait for science to determine if we too can reset our genes, there are many other ways to slow the aging process and reset our biological clocks, Sinclair said.

"The top tips are simply: Focus on plants for food, eat less often, get sufficient sleep, lose your breath for 10 minutes three times a week by exercising to maintain your muscle mass, don't sweat the small stuff and have a good social group," Sinclair said.

What controls the epigenome? Human behavior and one's environment play a key role. Let's say you were born with a genetic predisposition for heart disease and diabetes. But because you exercised, ate a plant-focused diet, slept well and managed your stress during most of your life, it's possible those genes would never be activated. That, experts say, is how we can take some of our genetic fate into our own hands.

Cutting back on food -- without inducing malnutrition -- has been a scientifically known way to lengthen life for nearly a century. Studies on worms, crabs, snails, fruit flies and rodents have found restricting calories "delay the onset of age-related disorders" such as cancer, heart disease and diabetes, according to the National Institute on Aging. Some studies have also found extensions in life span: In a 1986 study, mice fed only a third of a typical day's calories lived to 53 months -- a mouse kept as a pet may live to about 24 months.

Studies in people, however, have been less enlightening, partly because many have focused on weight loss instead of longevity. For Sinclair, however, cutting back on meals was a significant factor in resetting his personal clock: Recent tests show he has a biological age of 42 in a body born 53 years ago.

"I've been doing a biological test for 10 years now, and I've been getting steadily younger for the last decade," Sinclair said. "The biggest change in my biological clock occurred when I ate less often -- I only eat one meal a day now. That made the biggest difference to my biochemistry."

Additional ways to turn back the clock

Sinclair incorporates other tools into his life, based on research from his lab and others. In his book "Lifespan: Why We Age and Why We Don't Have To," he writes that little of what he does has undergone the sort of "rigorous long-term clinical testing" needed to have a "complete understanding of the wide range of potential outcomes." In fact, he added, "I have no idea if this is even the right thing for me to be doing."

With that caveat, Sinclair is willing to share his tips: He keeps his starches and sugars to a minimum and gave up desserts at age 40 (although he does admit to stealing a taste on occasion). He eats a good amount of plants, avoids eating other mammals and keeps his body weight at the low end of optimal.

He exercises by taking a lot of steps each day, walks upstairs instead of taking an elevator and visits the gym with his son to lift weights and jog before taking a sauna and a dip in an ice-cold pool. "I've got my 20-year-old body back," he said with a smile.

Speaking of cold, science has long thought lower temperatures increased longevity in many species, but whether it is true or not may come down to one's genome, according to a 2018 study. Regardless, it appears cold can increase brown fat in humans, which is the type of fat bears use to stay warm during hibernation. Brown fat has been shown to improve metabolism and combat obesity.

Sinclair takes vitamins D and K2 and baby aspirin daily, along with supplements that have shown promise in extending longevity in yeast, mice and human cells in test tubes.

One supplement he takes after discovering its benefits is 1 gram of resveratrol, the antioxidant-like substance found in the skin of grapes, blueberries, raspberries, mulberries and peanuts.

He also takes 1 gram of metformin, a staple in the arsenal of drugs used to lower blood sugars in people with diabetes. He added it after studies showed it might reduce inflammation, oxidative damage and cellular senescence, in which cells are damaged but refuse to die, remaining in the body as a type of malfunctioning "zombie cell."

However, some scientists quibble about the use of metformin, pointing to rare cases of lactic acid buildup and a lack of knowledge on how it functions in the body.

Sinclair also takes 1 gram of NMN, or nicotinamide mononucleotide, which in the body turns into NAD+, or nicotinamide adenine dinucleotide. A coenzyme that exists in all living cells, NAD+ plays a central role in the body's biological processes, such as regulating cellular energy, increasing insulin sensitivity and reversing mitochondrial dysfunction.

When the body ages, NAD+ levels significantly decrease, dropping by middle age to about half the levels of youth, contributing to age-related metabolic diseases and neurodegenerative disorders. Numerous studies have shown restoring NAD+ levels safely improves overall health and increases life span in yeast, mice and dogs. Clinical trials testing the molecule in humans have been underway for three years, Sinclair said.

"These supplements, and the lifestyle that I am doing, is designed to turn on our defenses against aging," he said. "Now, if you do that, you don't necessarily turn back the clock. These are just things that slow down epigenetic damage and these other horrible hallmarks of aging.

"But the real advance, in my view, was the ability to just tell the body, 'Forget all that. Just be young again,' by just flipping a switch. Now I'm not saying that we're going to all be 20 years old again," Sinclair said.

"But I'm optimistic that we can duplicate this very fundamental process that exists in everything from a bat to a sheep to a whale to a human. We've done it in a mouse. There's no reason I can think of why it shouldn't work in a person, too."

& 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

See the article here:
The 'Benjamin Button' effect: Scientists can reverse aging in mice. The goal is to do the same for humans - KITV Honolulu

Have something to say? Lookout welcomes letters to the editor, within our policies, from readers. Guidelines here.

Like many moms, UC Santa Cruz stem cell biologist Lindsay Hinck struggled to make enough milk to feed her infant daughter.

Frustrated by her low supply, she went to a lactation consultant, who advised her to wake up every night at 3 a.m. an optimal time in the hormone cycle to pump precious drops of liquid gold for her baby.

Hinck did it, but she also wondered, why was she having so much trouble and losing so much sleep while other moms had no problem feeding their newborns?

After many exhausting early hours with the pump, Hinck did what she does best: research. She found something remarkable: More than 25% of women worldwide struggle to produce enough milk to feed their infant children.

But when she looked to scientific literature for an explanation, it came up empty.

Hinck, who got a masters degree in biochemistry from UC Davis and her Ph.D. in cancer biology from Stanford University, was shocked to realize scientists have barely studied human lactation. There was almost no information for scientists or moms about how human breast tissue makes milk.

Hinck decided to change that.

She switched her UCSC labs research focus from breast cancer to lactation, specifically looking into how stem cells in breast tissue create milk and why some womens supply comes out low.

Its a topic some view with skepticism; lactation and breastfeeding are still treated by many as uncomfortable or inappropriate. In fact, in the early days of her research, Hinck had to get funding from an animal health firm interested in increasing milk production in cows.

We sexualize breasts in the most amazing ways, and people dont seem to have a problem talking about that, says Hinck, who has been at UCSC since 1998 and serves as co-director of the universitys Institute for the Biology of Stem Cells. Yet when it gets down to their biological function which is to provide nutrition for infants somehow the world clams up.

With the a nationwide baby formula shortage having affected millions of families, Hincks work funded by the National Institutes of Health takes on even greater importance. Parents whose infants have allergies or metabolic conditions rely on formula, and women particularly those who are already struggling to breastfeed cant suddenly build a milk supply overnight when formula is not available.

Hinck spoke with Lookout from her office at UCSC; this interview has been edited for clarity.

Lookout: What is lactation insufficiency?

Lindsay Hinck: Lactation insufficiency is the inability of a woman to produce the breast milk in daily volumes that meet the nutritional needs of her infant.

The statistics that we have are very broad. Somewhere between 25% and 67% of women will experience this worldwide. And this statistic is so broad because lactation insufficiency is understudied, and its hard to study.

A lot of scientists would agree that breast milk does confer an immunological advantage, and that it is filled with immune cells that the mother is giving to her infant; milk is also filled with microbes. Those are two of the major deliveries to children that come through breast milk, not to mention all the comfort of the breastfeeding cycle, psychological comfort and connectedness through the skin on skin feeling of being fed that way.

Lookout: How do you feel about your research in the context of the baby formula shortage?

Hinck: A lot of women rely on formula because they have trouble building a milk supply. Currently there are no FDA (U.S. Food and Drug Administration)-approved drugs in the United States for lactation insufficiency. My research is identifying therapeutically relevant drug targets, so that maybe we will be able to address this issue. We hope that one day women can take a drug to better build a milk supply.

Were working on a nonhormonal drug. The current drugs work on the hormone prolactin, whereas my lab studies stem cells. None of the drugs targeting prolactin have been approved, because they have terrible side effects.

Hormones have wide-ranging effects. Theyre released and they spread throughout the body. I think maybe we have an opportunity to identify a therapeutic that wont have so many deleterious side effects.

(Mel Melcon / Los Angeles Times)

Lookout: Because of the baby formula shortage, an easy answer might be to tell mothers they should just breastfeed. Why might that not be a compassionate or realistic response?

Hinck: No, thats not a compassionate or realistic response. I mean, especially if you havent built your milk supply, its not a trivial thing. If you didnt build a milk supply from the beginning, and even if you are breastfeeding, if you cant meet the daily needs of your infant, you simply dont have the milk. Its just not there.

Building a milk supply doesnt occur over 24 hours, you cant just latch the child on more often and have more milk in a day. Eventually the milk supply will increase, but its complicated. Its hard for some women to initiate and build a milk supply.

Lookout: In the U.S., lactation and breastfeeding seem to be treated as somewhat taboo or uncomfortable topics. How do you respond to that?

Hinck: We dont want to see women doing it. It seems to make people uncomfortable, so at best we provide women a room somewhere, and at worst there are no accommodations. We certainly dont appear as a society that welcomes breastfeeding in public. I am bemused at this, and find it tragic at the same time.

I myself, when I breastfed, I just breastfed. I just got to the point where tough, you know? I know I made people uncomfortable. My mother-in-law would try to drape a huge blanket over me and my child in the summer in the heat, and it was like 100 degrees underneath that blanket. I would just be like, This is crazy! Its just an infant at my breast eating. Seems fine to me. And I dont think the climate has dramatically changed in many places in the world. My daughter is 22 years old, and in 22 years I have not seen that needle budge. It still seems like breastfeeding makes people uncomfortable, and I dont know why.

Lookout: Have you faced any skepticism about this as a research topic, or faced any particular challenges in studying lactation compared to other topics, like cancer?

Hinck: I would say that I have had a harder time getting my lactation research funded. But recently, I received a NIH grant from the National Institutes for Child Health and Human Development, so thats been terrific. There has been a gaining interest in a number of whats been classified as womens diseases that have been understudied for a long time.

But in the early days, I got money from an animal health firm because they were interested in increasing milk supply in cows. The biology is the same, however. So that worked out for me, and we were able to have a project that involves looking to see if this would work for building milk supply in cows, and then we were able to unravel the basic pathways, and now were applying that.

Lookout: What would you say are the big questions driving your current research?

Hinck: How does the breast tissue know how many progenitor cells to release or recruit to expand and to build the milk supply?

Breast stem/progenitor cells have to last a whole lifetime, and they have limited potential. Theyre stemlike in that they undergo an asymmetric cell division, which is a special type of cell division that recreates the stem/progenitor cells and gives rise to daughter cells that can go on to expand and become the milk producing cells.

So how many of those asymmetric cell divisions occur? How many cells are recruited to undergo those asymmetric cell divisions? All of that is unknown. Remember, the stem cell, the progenitor cell, wants to divide as infrequently as possible. Every time they replicate their DNA, it is opening up the possibility of damage that could lead to cancer.

Lookout: How would understanding these progenitor cell pathways help improve peoples lives, or pursue a solution to lactation insufficiency?

Hinck: Its early days. We dont understand a lot, and of course giving drugs to women who are pregnant is tough. There are drugs on the market for lactation domperidone is the best medicine to build milk supply, but its not approved by the FDA in America. It has side effects, cardiac side effects.

So its not unheard of that there would be drugs that could help build a milk supply. I think that would be the ultimate goal of our research, to understand if there is any pharmacological intervention that could help.

Lookout: What do you think nursing mothers who are struggling with lactation need? What can we do as a society to support them?

Hinck: Well, in the short term, certainly make workplace rules that change the climate. I mean, even if the rules are in place, if women dont feel welcome to take the breaks to pump then it doesnt happen. I mean, we all know how that goes.

Give mothers more time off. Create more welcoming environments when they come back to work to support them and their desire to breastfeed their child.

And in the longer term, we could understand the biology of building milk supply, which is still quite mysterious in humans. What are some of the factors that may impinge on that during pregnancy or after pregnancy?

Lookout: What did you have to do in order to feed your child when you were having trouble making enough milk?

Hinck: I saw the lactation consultant and I was told to pump at 3 a.m. when prolactin levels are the highest. I would set the alarm and get up and pump every night. I was also working full time, pumping every four hours. But I could barely pump the amount of milk for the next day.

Thats a burden, you know? Its just hard to balance. Youve got an infant, and youve got this other role, but youre also providing all the food for them. It doesnt always work seamlessly, thats for sure. I went to work to do my science, and I did the best I could.

It was a lot of work. Its so much to expect of mothers. And we just dont give parents, mothers, the space and time to breastfeed at work. Its also underappreciated that there could be other people who want to breastfeed, and we need to open doors for them for non-birth moms, trans people. Why do we keep lactation in just the realm of women? I think that if we understood lactation physiology better, we could help people breastfeed.

Guanan Gmez-Van Cortright is a 2022 graduate of the UC Santa Cruz Science Communication masters program. She has written for Good Times, KQED radio and the San Jose Mercury News.

See the original post:
Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz

1. CRISPR 'cousin' put to the test in landmark heart-disease trial  Nature.com
2. CRISPR cure for high cholesterol enters first human trial  Freethink
3. Boston biotech Verve tests 'CRISPR 2.0 in a patient for the first time  The Boston Globe
4. Edits to a cholesterol gene could stop the biggest killer on earth  MIT Technology Review
5. Verve starts first human test of gene editing treatment for heart disease  BioPharma Dive
6. View Full Coverage on Google News

Original post:
CRISPR 'cousin' put to the test in landmark heart-disease trial - Nature.com

Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care recession-proof?

We cover all that and more this week on The Readout LOUD, STATs biotech podcast. Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the companys work on preventing heart disease with genome editing. Then, STATs Isabella Cueto joins us to discuss Hot girls have IBS, an internet in-joke that evolved into a movement for people with chronic illness. We also break down the latest news in the life sciences, including a long-awaited victory for Novavax and ostensible good news for biotech.

For more on what we cover, heres the latest on Verve; heres the story on hot girls have IBS; heres the news on Novavax;heres where you can find episodes of Color Code; heres where you can subscribe to the First Opinion Podcast;and heres our complete coverage of the Covid-19 pandemic.

advertisement

Be sure to sign up on Apple Podcasts, Spotify, Stitcher,Google Play, or wherever you get your podcasts.

And if you have any feedback for us topics to cover, guests to invite, vocal tics to cease you can email [emailprotected].

The rest is here:
CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl' - STAT

BOSTON Researchers from the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine used variants of CRISPR to understand the functions of the genes that cause emphysema and chronic obstructive pulmonary disease (COPD). Published in Science Advances, researchers discovered functional consequences by turning off the expression of the gene that contributes to the pathogenesis of these diseases.

This is the first time that CRISPRi and CRISPRa have been applied in human induced pluripotent stem cells to understand the functional role of these genes, says Andrew Wilson, MD, a pulmonologist at Boston Medical Center and associate professor of medicine at Boston University School of Medicine. It gets us closer to understanding how inherited factors help contribute to susceptibility to emphysema.

COPD and emphysema is the third leading cause of death worldwide, creating a significant burden of disease. Emphysema is a complex genetic disease caused by a mutation or variant in a number of genes that contribute to making some individuals more susceptible to disease than others. Genome-wide association studies (GWAS) have implicated variants in or near a growing number of genes, but understanding their functions and how they potentially contribute to the development of COPD and emphysema is quite limited.

There have been no new significant pharmacological agents developed to help treat the large number of patients afflicted with COPD or emphysema worldwide, says Rhiannon Werder, MD, a postdoctoral fellow at the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine. Our hope is that this study will help in the understanding of the genetics of the disease, improve our understanding of how the disease occurs at a cellular level, and support the development of new therapies to treat these conditions.

Researchers devised a system using variants of CRISPR to either turn off expression of a gene of interest using CRISPR interference (CRISPRi) or overexpress a gene of interest using CRISPR activation (CRISPRa) in induced pluripotent stem cells (iPSCs). Researchers grew these cells in a dish and differentiated them to generate cells that reside in the lung. The cell type studied is called the type 2 alveolar epithelial cell, a progenitor cell for the alveolus the alveolus is the part of the lung where gas exchange occurs and is the structure that is damaged in emphysema. So by understanding how GWAS genes affect type 2 cells, researchers can start to understand how these might contribute to diseases that affect these cells, like emphysema.

Once type 2 cells were generated, researchers then used CRISPRi to turn off expression of nine different GWAS genes and analyzed them to see how the cells were affected, especially their ability to proliferate, something that they need to be able to do in response to injury like that which occurs in emphysema. Researchers noticed that turning off one particular gene, desmoplakin (DSP), caused the cells to increase their proliferation and increased their expression of genes associated with cellular maturation. Researchers found that cells in which DSP expression was turned off before smoke exposure turned off expression of cell junction genes to a greater degree than in controls. These were also better at forming new colonies, a measure of progenitor function, than controls. Researchers then looked in mice that had DSP deleted from their lung epithelial cells, compared to control mice with normal DSP. Researchers found that the type 2 cells in the DSP deletion mice were more proliferative following injury, consistent with findings in human iPSC-derived type 2 cells.

DSP appears to modulate the proliferative capacity of type 2 cells at baseline and following injuries that are relevant to human disease, such as smoke exposure. Lower levels of DSP expression increase the proliferative capacity of type 2 cells in the system, potentially making them better able to respond to an injury. In contrast, higher levels of expression as found in cells containing the variant associated with COPD risk by GWAS appear to make the cells less proliferative after smoke exposure, potentially explaining how this gene contributes to disease.

Read the original post:
CRISPR Technology Highlights Genes That Contribute to the Development of Emphysema and COPD - Boston Medical Center

Kenneth Research

Key Companies Covered in the Global Gene Therapy Market by Kenneth Research are Kineta, Inc., Novartis AG, Amgen Inc., bluebird bio, Inc., Gilead Sciences, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

New York, July 13, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization (WHO), around 10 million deaths, or nearly 1 in 6 deaths, were caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. If found early and appropriately treated, many tumors (30% to 50%) are curable. According to the American Cancer Society (ACS), 1,918,030 new cancer cases and 609,360 cancer deaths are expected in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily in the United States.

In recent research titled Global Gene Therapy Market, Kenneth Research provided a brief overview of market elements including growth drivers, restraint factors, current market trends, and potential for future growth. The influence of COVID-19 and its effects on end-users are both thoroughly examined in the market research report, which covers the forecast period, i.e., 2022-2031. In addition, the research study examines the product portfolios and market expansion plans of the principal competitors.In 2020, according to the World Cancer Research Fund (WCRF), there were 18 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. The growth of the global gene therapy market can be attributed on account of the rising prevalence of cancer cases. Also, the adoption of gene therapies for the treatment of cancer is predicted to grow the market further. For instance, at the University of Pennsylvania, the first trial for testing a CRISPR-created cancer medicine was launched in the United States in 2019.CRISPR is a gene-editing-tool, that can modify any DNA segment within the 3 billion letters of the human genome. The global gene therapy market is expected to gather around USD 6 billion in revenue by 2031 and grow with a CAGR of ~34% over the forecast period. Get A Sample Copy of This Report @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. On the back of rapid rising cancer incidence rates, and the availability of high disposable income, the market in North America is predicted to experience significant expansion over the course of the forecast period. For instance, the Cancer Facts & Figures 2021 by the American Cancer Society, the study estimates that 1.9 million new instances of cancer were diagnosed and 608,570 cancer deaths in the United States in 2021. Also, an increase in the demand for gene-therapy-related R&D activities further helps the growth of the market. According to the World Bank Data, the domestic general government healthcare expenditure in the U.S. was 5,552.60 IN 2019 whereas in Canada the domestic general health care expenditure was 3,873.70 in 2019. Thus, a rise in government health care support is expected to expand the gene therapy-related R&D activities and further aid on to improve the market in the region.On the other hand, the global gene therapy market in the Asia Pacific region is anticipated to experience the greatest CAGR throughout the forecast period owing to the growing population in the region and increased approval and availability of gene therapy products. According to the World Bank data, the total population of China was 1.41 billion in 2020 whereas, India had 1.38 billion people in 2020. As the population grows, the likelihood of contracting a disease increases. Additionally, it is anticipated that increased government efforts to upgrade the health care infrastructure and rising healthcare costs in that region are expected to expand the industry. Also, the health care expenditure in Japan in 2019 was 10.74% whereas, in China, the GDP was 5.35%. In addition to that, the domestic general government health expenditure per capita for Japan was 3,846.54 in 2019 and China was 492.72 in 2019. Thus, growing health care expenditure and government support in health care expansion are further expected for the growth of the market in the region.

Browse to access In-depth research report on Gene Therapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/gene-therapy-market/10070542

The study further incorporates Y-O-Y Growth, demand & supply and forecasts future opportunities in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC[Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia Pacific(China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa(Israel, GCC[Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa).The global gene therapy market is segmented by indication into cancer, metabolic disorders, eye disorders, cardiovascular diseases, and others. Among that the cancer segment is predicted to hold the largest share over the forecast period. On account of the growing widespread presence of cancer cases, the growth of the market can be accredited. The estimated number of new cases of cancer patients in India was around 11,57,294 cases which had risen to 13,24,413 total cases in 2020. In addition to that, the total number of cancer patients was 1,708,921 in 2018 in the U.S., according to the Centers for Disease Control and Prevention (CDC) which got increased to an estimated rate of 1.8 million new cases in 2020. The statistical studies exhibit an increasingly widespread of the disease worldwide which is expected to drive the growth of the segment. Gene therapies are used to treat a variety of malignancies, including those of the brain, lung, breast, pancreatic, liver, prostate, bladder, head & neck, skin, and ovary. For instance, according to the World Cancer Research Fund (WCRF), the most common cancers around the world were breast and lung cancers, accounting to 12.5% and 12.2% respectively of all new cases that were expected to be diagnosed in 2020. Also, there were 1.9 million new instances of colorectal cancer, accounting for 10.7% of all cancer cases in 2020.

Get a Sample PDF of Global Gene Therapy Market @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented by end-user into pharma & biotech, and academia. Numerous ongoing researches and studies have been conducted in the pharma and biotech sector which is anticipated to account for the growth of the segment. For instance, based on a study by PhRMA, there were 289 gene therapies done in clinical development by biopharmaceutical companies in 2018 which had increased to 362 gene therapies in 2020. Also, 6 diseases were already being treated using gene therapy, whereas 362 cell and gene therapies were in the development stage in 2020. In addition to that, 9 cell or gene therapy products have been approved by U.S. Food and Drug Administration (FDA) as of February 2020; they are used to treat cancer, eye conditions, and uncommon inherited diseases.

The global gene therapy market is also segmented on the basis of technology and application.

Global Gene Therapy Market, Segmentation by Technology:

Global Gene Therapy Market, Segmentation by Application:

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070542

Some of the well-known leaders in the global gene therapy market that are included in our report are Kineta, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

Browse More Related Reports:

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinsons Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

Here is the original post:
Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031; Market to Grow on...

While Cesarean delivery remains the most common surgical procedure among women of reproductive age, hysterectomy isnt far behind, according to Johns Hopkins Medicine. The second most common surgery for women of childbearing age, hysterectomy involves the surgical removal of the womb. It can be performed using three different techniques: vaginal, abdominal, and laparoscopic.

According to the National Womens Health Network, approximately 600,000 hysterectomies are performed each year.

In fact, about one-third of American women will have had a hysterectomy by the age of 60, statesBrigham and Womens Hospital.

However, Dr. Jennifer Lang, an obstetrician-gynecologist and gynecological oncologist based in Los Angeles, believes hysterectomies are over-performed.

I consider removing this particular organ as a very radical and extreme act that should be only proceeded with after a thorough review and trial of every other less extreme option that is out there, Lang, who sees the uterus as a sacred organ that plays a spiritual role in a womans life, told The Epoch Times.

When nonmalignant tumors cause heavy bleeding and pelvic pain, doctors will often recommend a hysterectomy. Without a uterus, a woman no longer experiences painful periods.

Endometriosis is a condition in which uterine tissue extends outside of the uterine walls and attaches to the ovaries, intestines, or fallopian tubes. This can cause severe bleeding and pelvic pain.

Uterine prolapse occurs when the uterus falls out of its normal position due to the weakening of the ligaments. A woman who has a prolapsed uterus often feels pressure in her lower abdomen and may not be able to fully empty her bladder.

In a 2016 study conducted by Duke Cancer Institute, scientists observed that women with the BRCA1 gene were specifically at risk for uterine carcinomas.

Some women who have the BRCA gene elect, after a recommendation from their doctor, to get a prophylactic hysterectomy to reduce their likelihood of developing cancer.

While you may think hysterectomieslike mastectomiesare mostly performed to prevent or treat cancer, only 10 percent of hysterectomies are to treat cervical, endometrial, or ovarian cancer, according to Johns Hopkins Medicine.

The hysterectomy procedure dates all the way to the Middle Ages when it was done in a more barbaric and dangerous way than it is today. They were previously conducted to remove a prolapsed uterus.

Early hysterectomies were performed without anesthesia.

The mortality rate was around 70 percent, according to the journal Clinical Obstetrics and Gynaecology. Women who were lucky enough to survive the operation often died shortly afterward from complications, which ranged from inflammation of the abdominal wall, hemorrhage, and sepsis.

Hysterectomies became safer in the 20th century as the complications decreased with the invention of anesthesia and antibiotics.

The current mortality rate from a hysterectomy is thought to be less than 1 percent, according to the National Womens Health Network. While this may seem reassuring, with 600,000 hysterectomies performed a year in the United States, these numbers suggest that thousands of women die from these operations every year.

A hysterectomy is surgical menopause. Pregnancy isnt possible afterward, and most women need to take hormones for the rest of their lives. That has been an ongoing source of sadness for my friend whom well call Anna. Anna felt she wasnt adequately counseled by the surgeon who removed her womb. Now, in her early 50s, she and her partner are trying to have a baby via surrogacy using donor eggs.

Complications are possible with any type of major surgery. Some of the short-term risks from getting a hysterectomy, according to Stanford Health Care, include allergic reaction to anesthesia, blood clots, blood loss, damage to surrounding organs, and infection.

Dr. Shannon Laughlin-Tommaso, an obstetrician-gynecologist who works at the Mayo Clinic in Rochester, Minnesota, conducted a longitudinal study for more than 20 years. She analyzed more than 2,000 women who had a hysterectomy for benign gynecological diseases.

That study, published in 2018, found that women who had hysterectomies were at increased risk for hypertension, high cholesterol, obesity, and even cardiac abnormalities.

The same sample of women was also analyzed in a separate longitudinal study published in 2019 in the peer-reviewed journal Menopause. Women post-hysterectomy, researchers discovered, were at an increased risk for anxiety and depression.

The risk of depression was even higher for women who underwent a hysterectomy between the ages of 18 and 35.

Laughlin-Tommaso is critical of the procedure. Because women often get a hysterectomy at a young age, knowing the risks associated with the procedure even years later is important, she told a reporter for the Mayo Clinic. Our study shows that removing the uterus may have more effect on physical and mental health than previously thought.

In 2021, the FDA approved the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients. Because it enables surgeons to perform hysterectomies remotely, without needing to touch the patient, RASD has become an even more common method during COVID, according to Nature Machine Intelligence.

This technique surgeons to use computer-generated software to maneuver surgical instruments through tiny incisions in the patients body to remove the uterus through the vagina, rather than through the abdomen. A video camera is inserted laparoscopically through a small incision in the abdomen so that the instruments inside the patient are visible.

In 2021, the FDA conducted a clinical study of 30 patients undergoing transvaginal hysterectomy using the Hominis Surgical System to test its safety and effectiveness.

Patients ranged in age from 37 to 79 years old. More than half had comorbidities, including high cholesterol, hypertension, and osteoporosis.

According to the FDA, all 30 patients underwent successful hysterectomies via this new technique. Minor complications, such as blood loss and urinary tract infections, occurred.

While this seems promising, the study had several flaws. If the patients procedure didnt have to be converted to a traditional method of hysterectomy, it was considered successful. In addition, study participants were only followed for six weeks after the surgery. Whether they suffered long-term adverse effects is unknown.

But we do know about problems with another robotic hysterectomy method, the da Vinci System, which was cleared for use by the FDA in 2005.

In a 2009 study published in the journal Obstetrics and Gynecology, 510 patients were followed after their procedures were performed with the da Vinci. Twenty-one patients reported dehiscence (opening) of the surgical wound in the vagina. Six of the patients bowels prolapsed transvaginally.

A 2018 investigation by NBC found that in a 10-year period there were more than 20,000 adverse events caused by the da Vinci reported to the FDA.

Of those, 17,000 were device malfunctions, including parts of the device falling off into patients bodies, and 274 were deaths.

NBC also reported that training programs for surgeons to use the da Vinci werent required.

In 2015, Laurie Featherstone received a da Vinci hysterectomy. Weeks after her robotic-assisted operation, excess fluid filled her kidneys. Her ureter and colon had been burned by the device. She will use a colostomy bag for the rest of her life.

Despite her doctors reassurance that the robotic technique would lead to fewer complications, Featherstone now lives with permanent health problems.

I put all my faith in the doctor and didnt ask questions, Featherstone told NBC.

A 2015 study published in the American Journal of Obstetrics and Gynecology revealed that nearly 40 percent of hysterectomies may not be necessary.

This study analyzed the use of alternative treatments prior to a hysterectomy for women with benign conditions. They examined the medical records of 3,397 women who underwent hysterectomies.

Some of the results were shocking:

If these numbers are correct, of the 600,000 hysterectomized women in the United States, some 120,000 didnt need the procedure.

It seems women with benign gynecologic conditions arent being informed of alternative medical and natural treatments. Many doctors offer hysterectomies to women who may not need them without first considering less invasive methods.

Women with uterine fibroids can get a myomectomy, which surgically removes the fibroid while keeping the uterus intact. The Mayo Clinic describes the procedure as involving the removal of fibroids either through an incision in the abdomen or minimally invasive techniques through the belly button or vagina.

Myolysis is another alternative a woman can receive to treat fibroids. A gonadotropin-releasing hormone agonist is first given to decrease the size of the fibroid. The procedure is then performed by inserting a laser fiber or electrode into the fibroid to shrink it.

Women who experience heavy menstrual bleeding can also try endometrial ablation. This is a less invasive procedure that removes the uterine lining via electricity, fluids, cold, or balloon therapy, among others.

According to the NIH, hormone therapy may also be effective in treating endometriosis without needing a hysterectomy.

Dr. Aviva Romm, an integrative family physician who studied at Yale University, encourages her patients to focus on preventing fibroids in the first place and healing endometriosis naturally.

According to Romm, three lifestyle changes are key.

A 2016 study in the Journal of Obstetrics and Gynaecology Research found that a diet rich in cruciferous vegetables and fruits was correlated with reducing uterine fibroids.

An added benefit to eating fresh vegetables is that it can help cure endometriosis, Romm noted in an article, The Natural Approach to Endometriosis: Getting to Your Root Causes.

Consuming an excess amount of milk products causes an increase in estrogen levels. Uterine fibroids thrive in high-estrogen environments. Integrative doctors believe that dairy triggers the inflammatory process associated with endometriosis.

Endocrine-disrupting chemicals, as defined by the Endocrine Society, are substances in the environment, food sources, personal care products, and manufactured products that interfere with the normal function of your bodys endocrine system.

High exposure to these chemicals is known to increase fibroid growth. Everything you can do to reduce your exposure to these chemicals, including drinking out of glass instead of plastic, using chemical-free cosmetics, and eating organic produce, will help, Romm said.

There was a whole generation of obstetricians who were trained to believe that after a woman has reached menopause, her uterus was just an excess object that could cause problems if left inside, Lang said.

As more uterus owners are entering the surgical field, Lang hopes unnecessary hysterectomies will become less common.

Hysterectomies are fueled by the business of medicine and reimbursement for procedures, Lang insisted. Theres money there. Thats the darker side of medicine that we cannot ignore.

Read the original:
Did You Need That Hysterectomy? - The Epoch Times

Last term, Drexel University professors were recognized for their scholarly research and prolific academic and professional contributions. This update offers a snapshot of activity courtesy of the Office of the Provost.

Sponsored Research

Jina Huh-Yoo, PhD, an assistant professor in the Department of Information Scienceat the College of Computing & Informatics, was selected by the National Science Foundation (NSF) to receive a Faculty Early Career Development Award (CAREER). A CAREER award is NSFs most prestigious award in support of early-career faculty who have the potential to serve as academic role models in research and education and lead advances in the mission of their department or organization. The award provides $599,993 in funding over five years for Huh-Yoos project titled A Platform for Co-Designing and Understanding the Roles of Conversational Artificial Intelligence Systems on Caregiving. The project aims to advance the state of the art of human-centered artificial intelligence, particularly in investigating the roles conversational AI systems can play in supporting caregivers (e.g., parents, guardians, family members) and how domain experts and caregivers can work together to define these roles.

College of Nursing and Health Professions professors Glenn Williams (co-investigator, or Co-I), PhD, assistant dean of health sciences, associate professor, chair of physical therapy and rehabilitation sciences and executive director of the doctor of physical therapy program, and Ben Binder-Markey (Co-I), DPT, assistant professor of physical therapy and rehabilitation science, with College of Medicine professor Simon Giszter, PhD, (principal investigator, or PI) received $147,000 for their project Prototype Electrode for Intramuscular Single Unit Myography and Electrodiagnostic.

A collaboration between Minjung Shim (PI), PhD, assistant research professor in creative arts therapies, and Co-I Kathleen Fisher, PhD, professor of graduate nursing in the College of Nursing and Health Professions; Arun Ramakrishnan, PhD, director of research labs in the College of Nursing and Health Professions; and Fengqing Zhang, PhD, associate professor of psychology in the College of Arts and Sciences received $96,000 for At-Home Telehealth Mindfulness-based Dance/Movement Therapy for Older Adults with Mild Cognitive Impairment: A Feasibility Study from Commonwealth Universal Research Enhancement (CURE) 2021 Formula Grant Program and Pennsylvania Department of Health Grant.

Naomi Goldstein, PhD, professor of psychological and brain sciences in the College of Arts and Sciences, was awarded an$846,480 grant from the National Institute of Justice for her project, Reducing School Violence and Enhancing School Safety: Implementing and Evaluating the Positive School Safety Program for School Climate Staff. The project explores the role of poorly supervised and unstructured time in regards to school-on-school violence and if skilled supervision can address this.

Jrn Venderbos, PhD, assistant professor in the Department of Physics in the College of Arts and Sciences and the Department of Materials Science and Engineering in the College of Engineering, received a five-year,$551,286 National Science Foundation Faculty Early Career Development Grant (NSF-CAREER) award from the Condensed Matter and Materials Theory program in the Division of Materials Research. His project, CAREER: Advancing the Many-body Band Inversion Paradigm for Correlated Quantum Materials, will allow his group to lay the theoretical groundwork for better understanding the impacts of strong electronic correlations in materials with band inversion.

Brian Wigdahl, PhD, professor and chair of microbiology and immunology in the College of Medicine, received a $704,060 grant from the National Institutes of Health (NIH) for Broad Spectrum HIV Gene Editing Strategies in Peripheral and Brain Reservoirs.

The Robert Wood Johnson Foundation awarded the Dornsife School of Public Health a $300,000 grant to support its scholars and their research as part of their Transforming Academia for Equity program. With this support, Dornsife is sustaining and creating the structures, policies and culture changes needed to ensure both the academic success of diverse scholars and the production of scientific knowledge relevant to eliminating health inequities. The project will be led by Scarlett Bellamy, ScD, professor and associate dean for diversity and inclusion, and Rene H. Moore, PhD, research professor, director of the Biostatistics Scientific Collaboration Center and director of diversity, equity and inclusion for the Department of Epidemiology and Biostatistics.

Alina Schnake-Mahl, ScD, assistant research professor in health management and policy in the Urban Health Collaborative and the Department of Health Policy and Management in the Dornsife School of Public Health, was awarded a five-year, $637,000 K01 grant from the National Institutes of Allergy and Infectious Diseases to study the social and policy determinants of COVID-19 and influenza disparities.

Delia Solomons, PhD, assistant professor in the Antoinette Westphal College of Media Arts & Design, received a Henry Moore Foundation grant to support the writing of a catalog of the Venezuelan artist Marisols retrospective at the Albert-Knox Gallery in 2023.

Sriram Balasubramanian (PI), PhD, associate professor in the School of Biomedical Engineering, Science and Health Systems, received a five-year, $1.9 million NIH R01 grant for the project titled, Investigating Injury Mechanisms and Prevention Strategies for Brachial Plexus and Concomitant Spinal Cord Injuries in Neonates.

Joshua Snyder, PhD, associate professor of chemical and biological engineering in the College of Engineering, received an award from the Lawrence Berkeley National Laboratory for his project entitled Advanced PILBCP Ionomer Composites for Durable Heavy-Duty Proton-Exchange Membrane Fuel Cells (PEMFC). This project presents a strategy to achieve an improvement in performance and efficiency at higher average operational voltages and mitigate many of the sources of active area and activity loss over an extended PEMFC lifetime.

Kenneth Lau, PhD, professor and associate department head of chemical and biological engineering in the College of Engineering, is the sub-recipient with the University of Delaware for an award from the National Science Foundations Partnerships for Innovation (PFI) program. The PFI Program offers researchers the opportunity to perform translational research and technology development, catalyze partnerships and accelerate the transition of discoveries from the laboratory to the marketplace for societal benefit. Laus project, Next Generation, Conformable, Hybrid Heterojunction Solar Cells, focuses on the development of high-efficiency, inexpensive, flexible and conformable solar cells based on the hybrid organic-silicon heterojunction technology.

Christian Resick, PhD, associate professor of management in the Bennett S. LeBow College of Business, is a co-investigator on Taking Science to the Streets: Fire Service Safety Culture Assessment and Training, a study by the Dornsife School of Public Health made possible through a $1.5 million grant from the Assistance to Firefighters Grant Program run by the Federal Emergency Management Agency and the Department of Homeland Security.

The School of Education and the Academy of Natural Sciences of Drexel University recently received a $1.35 million NIH grant to support early childhood education efforts that focus on science, math, nutrition and literacy skills.

The second round of Museum Innovation Fund grants through the Academy of Natural Sciences selected three new project proposals, including a project by Drexel product design faculty and students in the Antoinette Westphal College of Media Arts & Design. Employing a user-centered design process, Westphal students will work with high school students and Academy staff to co-create an innovative pop-up lab module for Water Year designed to engage the public in Philadelphias diverse neighborhoods.

The College of Medicines Partnership Comprehensive Care Practice received three years of funding ($857,672 per year) from the Ryan White HIV/AIDS Program of the Health Resources & Service Administration. These funds help support the practices medical providers, case management team, nutritionist and other support services.

Major Gifts, Honors and Recognition

Alexander Fridman, PhD, John A. Nyheim Chair Professor in the College of Engineering and director of the C. J. Nyheim Plasma Institute, received the ISPlasma Prize from the International ISPlasma Society and Applied Physics Society of Japan.

Robert McCracken Peck, senior fellow of the Academy of Natural Sciences, was elected to the American Philosophical Society.

Ebony White, PhD, assistant clinical professor in the Counseling and Family Therapy Department in the College of Nursing and Health Professions, is the 2021 Dr. Judy Lewis Counselors for Social Justice Award recipient. This award recognizes a person (or persons) who has (have) engaged in social justice and advocacy aimed at making the lives of others and/or communities better through empowerment, community organizing and/or systems change through active engagement.

Dave DeMatteo, JD, PhD, professor of psychological and brain sciences in the College of Arts and Sciences, received the 2021 Psyche Award for the Most Valuable Paper on Psychological Assessment. The award is presented annually by the Journal of Contemporary Psychotherapy, and his article, Use of the Psychopathy Checklist-Revised in legal contexts: Validity, reliability, admissibility, and evidentiary issues, published in the Journal of Personality Assessment, was selected from several hundred articles.

Alex Ortega, PhD, professor of health policy in the School of Public Health and director of the Center for Population Health and Community Impact, joined the NIH National Heart, Lung, and Blood Institutes Observational Study Monitoring Board for the Hispanic Community Health Study/Study of Latinos. The Hispanic Community Health Study/Study of Latinos is a multi-center epidemiologic study in Hispanic/Latino populations to assess the role of acculturation in the prevalence and development of disease and identify factors playing a protective or harmful role in the health of Hispanics/Latinos.

Jana Hirsch, PHD, assistant research professor in the Urban Health Collaborative in the Dornsife School of Public Health, was recognized through the NIHs Collaborative Cohort of Cohorts for COVID Research (C4R)as an Early Career Investigator Awardee. Hirsch and colleagues will be analyzing data from over 47,000 American adults to better understand COVID-19 risk and resilience.

Sharon L. Walker, PhD, dean and distinguished professor of civil, architectural and environmental engineering in the College of Engineering, was elected vice chair of the Engineering Deans Council of the American Society for Engineering Education (ASEE). The council is a consortium of deans from all the engineering colleges affiliated with ASEE, representing more than 90 percent of all U.S. engineering deans. Additionally, Dean Walker was elected to the College of Fellows for the American Institute for Medical and Biological Engineering (AIMBE). Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer.

Adam Fontecchio, PhD, professor of electrical and computer engineering in the College of Engineering, was elected as the next Director of the Center for the Integration of Research Teaching and Learning (CIRTL), a network of 42 research universities in the United States and Canada that provides evidence-based, forward-thinking professional development to students at the graduate level.

Andrew Magenau, PhD, assistant professor of materials science and engineering in the College of Engineering, has been appointed as a 2022 Fellow in the Air Force Research Lab Summer Faculty Fellowship Program at AFRL - Materials and Manufacturing. The program is a continuous 8- to 12-week summer program that allows fellows to perform high-quality and meaningful research at Air Force sites.

A $10 million gift to Drexel from Ron W. Disney, BS 72 commerce and engineering, and Kathy Disney includes the second-largest individual gift ever made to the LeBow College of Business. Overall, the gift will promote diversity, equity and inclusion and provide scholarship funds and program support for students from underrepresented backgrounds, including through the creation of funds supporting student advising, cooperative education, need-based scholarships, operational support, research and program innovation.

The Lindy Institute for Urban Innovation, housed in the Antoinette Westphal College of Media Arts & Design, received $5 million in grants from the family of the late Philip B. Lindy (19302013), a generous benefactor of Drexel University, which will significantly further the Lindy Institutes mission to forge innovative strategies to equitably advance Philadelphia and other cities across the country and globe. The donation, made by Alan, Elaine and Frank Lindy, is intended to support the philanthropic vision and interests of their father and is the latest in several significant gifts to Drexel from two generations of the Lindy family.

The Drexel Food Lab in the College of Nursing and Health Professions received $5,000 from Zo Pappas, her second $5,000 gift to this fund.

The Pennoni Honors College has received a $275,000 Teagle Implementation Grant for its Program in Civic Foundations for a sequence of courses for a scaled-up cohort of Honors Program freshmen. The Program in Civic Foundations grounds a civic sense of Philadelphia in history, philosophy and social justice. This follows the Teagle Planning Grant received in 2020-21.

Eight College of Medicine faculty members, two alumni, 25 residents and fellows and 50 MD students were inducted into the Alpha Omega Alpha Honor Medical Society. Four College of Medicine faculty members, three residents and 27 MD students were inducted into the Gold Humanism Honor Society.

See the article here:
Faculty Highlights: Recent Awards and Grants - Drexel University

Male Pattern Baldness is also known as Androgenic Alopecia is among the most common causes of hair loss in males which can start at the age of 20-25 years and by the age of 50, half of the males experience partial or complete baldness or hair loss. Yes, its pretty common to lose your hair and almost go bald in your early twenties and as the name indicates, its genetic in nature and affects a lot of young population nowadays.

It is a common form of hair loss seen in men as well as females. Hair is lost in a well defined pattern leading to recession of the frontal hairline, with time leading to baldness. Earlier stages of the disease exhibits thinning of hair, giving the impression of reduced hair density.

This condition is related to genes and male hormones where your genes regulate the male pattern of baldness which acts through hormones therefore, there is a risk that one could inherit a family history. If your father, uncle or grandfather are bald, there's a considerable probability you can't avoid a similar outcome but in rare cases, it might happen that the hair loss is not implicated by hereditary factors but the gene mutation begins from the carrier and might impact the future generation. Such cases are known as sporadic cases.

Causes:

In an interview with HT Lifestyle, Dr B L Jangid , Dermatologist and Hair Transplant Surgeon at SkinQure Clinic in New Delhi's Saket, revealed, Your genes and male sex hormones have a role in male pattern baldness. It is caused by the conversion of testosterone to Dihydrotestosterone (DHT), which shrinks hair follicles and slows hair growth. The growth phase, or anagen, of the hair cycle, which typically lasts between three and six years, is thought to be shortened by DHT to just a few weeks or months. Other causes include:

Hereditary or genetic factors

Aging is the common reason

Loss of essential nutrients & improper diet

Psychological pressure and anxiety.

Hormonal changes during puberty, pregnancy, and menopause

Chronic illnesses or autoimmune diseases

Female problems like PCOS issues

Environmental factors like pollution, dust, etc.

Echoing the same, Dr Shivaani Yadav, MD Dermatologist and Cosmetologist at Medanta Gurgaon and SAYAA MED in Gurgaon, said, AGA is caused by number of factors with main culprit being an androgen - dihydrotestosterone. Increased levels of this androgen in hair follicles leads to shorter cycle of hair growth. This results in shorter and thinner hair, over time leading to baldness. There is also evidence of AGA being related to certain medical conditions such as coronary heart disease, prostate enlargement and disorders of insulin resistance in men and polycystic ovary syndrome in women. Also, stress and dietary insufficiencies may add upto the hairloss.

Warning signs and symptoms:

According to Dr B L Jangid, when the regular cycle of hair development is altered, hair loss results. He said, Most hair remains in a growth phase during the usual hair-growing cycle (known as the anagen phase). Before it falls out and new hair begins to grow in its place, this phase lasts for roughly 4 years. For those suffering from male pattern baldness, due to hormone interruption, it might happen that the hair growth is compromised for 1 or 2 years instead of 4 years and the hair has a much shorter development period before it starts to fall out.

He added, Bald spots and hair loss are the outcomes of this process. It is identified by the hair loss on the top and front of the head, as well as a receding hairline along with hair thinning. You may eventually acquire a bald patch on top of your head that gets larger with time, and the hair on your crown (the top of your head) may also get thinner. Hair loss along the sides and back of your head is typically not a symptom of male pattern baldness.

Treatments:

Dr Shivaani Yadav shared, With the advancement of medical sciences, there are multiple treatment options to treat AGA. Some of the common topical formulations are of minoxidil 2%-10% solutions, combination of minoxidil & finasteride, redensyl solutions and peptides sprays. Oral medicines for the condition should always be advised by your dermatologist. Biotin supplementation along with various essential vitamins and minerals also helps in regularising normal hair growth cycle. Certain in clinic treatment options like PRP (platelet rich plasma) which is an autologous growth serum also gives great results when done on a regular basis. For some, whove lost a substantial amount of their hair, hair transplant is a go to option. Hair transplant is a safe procedure when done by experienced hands and under correct supervision. Also, not to underestimate the role of a happy state of mind as well as a healthy diet.

However, Dr B L Jangid insisted that since male pattern baldness is genetically inherited, it cannot be avoided. He said, When hair loss is still modest, some therapies for male pattern baldness are more effective. Since Male pattern hair loss is divided into 7 stages, asking your doctor for information and guidance as soon as possible is a sensible move if you are concerned about hair loss. Medicines can help in hair growth; baldness can be postponed. It is recommended to visit a board-certified dermatologist who can guide you with the right treatment after diagnosing your hair loss stage. Minoxidil 5% - It is a liquid that can be applied to the areas of the scalp experiencing hair loss twice per day. It boosts scalp blood flow and promotes hair development.

He further suggested, Finasteride 1 MG: You can take one pill of finasteride every day. It functions by lowering hormone levels that contribute to male pattern baldness. The only side effect of this medicine is that even at low doses, it may cause reduced sperm counts in some men. Platelet-rich plasma (PRP): It is an add-on therapy to control hair loss and thinning. Activated plasma high in platelets is injected into a patient's scalp using this non-surgical therapeutic approach to promote hair growth and thickness.

In a few, male patterns baldness is commonly accepted by males as a natural aspect of ageing but some men may find that hair loss impairs their confidence and lifestyle, especially those who start losing their hair at a younger age. Dr B L Jangid concluded, Although we cant completely treat male pattern baldness but certain treatments have high success rates in delaying hair loss and promoting growth and thickness of hair. Your doctor can advise you on the course of treatment that could be most appropriate for you. They can educate you on the possible negative effects of your medications. Therefore, in order to prevent any additional harm, it is absolutely crucial to understand the baldness pattern and to see a hair transplant expert for the right diagnosis and treatment.

Originally posted here:
Male Pattern Baldness: Causes, warning signs and symptoms, treatment - Hindustan Times

Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.

An FDA investigation revealed that the principal investigator and/or the team running the gene therapy trial at the University of Pennsylvania failed to disclose that before Gelsinger was treated, other patients had experienced alarming side effects and that monkeys administered the same engineered virus had died. The incident, coupled with dangerous outcomes involving other gene therapy treatments, had a chilling effect on the field and investors backed away.

Today, new approaches to gene therapy that include advances driven by CRISPR gene editing tools are raising hopes of a gene therapy revival. There are potential breakthroughs in the pipeline, including treatments for different types of cancer and sickle cell disease.

advertisement

Im concerned that gene therapy 2.0 is at risk of making the same mistakes that plagued the 1.0 version. Most notably, exciting work to translate gene therapy advances into safe, effective, and commercially viable treatments are at risk of being undermined by a reluctance to share data.

Im not saying that the field is on the verge of something analogous to the tragedy experienced in 1999. But the road to such extremes can be paved with a series of lesser nondisclosures that inhibit the free flow of scientific data essential for assessing potential risks long before treatments are given to people.

advertisement

I saw an example in May at the annual meeting of the American Society of Gene and Cell Therapy. A presenter was discussing a new approach for using gene therapy to treat a rare genetic disorder called Leber congenital amaurosis that causes blindness in children. The presenter discussed experiments in mice that involved disabling or deleting certain segments of a gene linked to the disorder, and this treatment appeared to at least slow the process of vision loss.

Assessing the safety and effectiveness of this potentially exciting advance requires knowing which regions of the gene were being modified. But when someone in the audience asked for more details, the presenter indicated that the information was proprietary and he would not disclose that. The exasperated questioner pointed out that the presenters approach was all about deleting [a segment of a gene], but you dont say what you are deleting. The response? Silence.

Tinkering with a particular genes function, even when the goal is to stop it from doing harmful things, can be risky. Knowing which region of a gene is being altered is essential for determining if solving one problem might create an even bigger one. For example, I and other scientists are interested in the potential of using CRISPR gene editing tools to disable a gene called nuclear factor erythroid 2-related factor 2 (NRF2), which produces a protein that protects a certain type of lung cancer tumor from the effects of chemotherapy or radiation. But that same gene confers a range of health benefits, such as withstanding toxic insults like nicotine or radiation or heat stress, and a poorly targeted edit might do more harm than good.

I am also regularly seeing a failure to disclose important details, like studies that use several strains of mice in a gene therapy experiment without clarifying which strain was linked to a particular result. That can make it difficult, or even impossible, to conduct a fundamental exercise in science: reproduce the results of other investigators. Reproducibility is a problem across all areas of science. But the stakes are higher in the fragile world of gene therapy, where investigators need to be doing all they can to protect patient safety.

My initial thoughts about the presenter who was loquacious in describing his success with gene therapy for Leber congenital amaurosis but quiet about revealing his methods was simply, If you arent willing to share your full information, dont present at scientific conferences.

I am not against protecting intellectual property or patenting biotechnology advances. Properly used, these strategies help attract investment that accelerates the search for transformative treatments. But researchers shouldnt come to a place where they benefit from everyone else freely sharing their findings but then refuse to reciprocate.

My broader message is that the field of gene therapy was once severely damaged by not sharing data that may have been able to prevent a young man from losing his life. Transparency in gene therapy research which can be accomplished without compromising commercial prospects is vital to success. One high-profile failure would badly hurt the revival of gene therapy; two would send it back into hibernation.

When everyone embraces transparency, all of our projects are likely to advance faster toward safe and effective treatments and everyone wins: scientists, investors and, most importantly, the people who could benefit from gene therapy.

Eric B. Kmiec is the executive director and chief scientific officer of the ChristianaCare Gene Editing Institute in Newark, Del.

Here is the original post:
Secrecy: A demon of gene therapy's past bedevils its future - STAT

Recently, a patient centricity concept has spread across all corners of the healthcare community with a straightforward goal: to improve and save patients lives through innovative and effective drug therapies adapted to patients' individual needs. However, for this concept to truly come to life, it is necessary to count on temperature-controlled supply chain logisticslike CRYOPDP to turn what could be a complex operation into a highly efficient process. This is extremely vital, because a patients life could literally be on the line with every shipment.Patient centricity in the clinical trial community involves meeting the patients where they are.The clinical trial industry is globalising and demands international healthcare logistics partners that can serve its growing and continuously evolving needs. For decades, temperature-controlled logistics experts have operated behind the scenes with patients barely aware of the hard work that went into their medicines journey. Thanks to the Covid-19 vaccine distributions impressive performance and its universal effect on people's health across the globe, it has become apparent to the world just how critical and important a logistics providers mission is for both patients and the industry.The endless pandemic lockdowns meant that patients could not travel to hospital sites for clinical trials due to travel and access restrictions. This led to a seismic shift where sponsors quickly moved to a direct-to-patient model to try to continue trials and keep patient treatments on schedule. As part of our response to this unique situation, CRYOPDP as a specialist in temperature-controlled logistics, with the mission to improve people's healthcare options, had to go further and dive deeper to better understand customers perceptions of the impact of the pandemic and work with them to provide those options.With the patient always at the centre of its business and considering the huge development of decentralised clinical trials, the development and implementation of a new service such as Direct-to-Patientseems to be the most natural evolution for CRYOPDP. We have been offering this turnkey solution completely adapted to patients needs, with the same efficiency and total peace of mind, to the benefit of many customers.This model makes life a lot easier for patients and their families, as they dont have to make multiple trips to a clinic or hospital that is potentially a great distance from their home. It is also beneficial for patients who may be too ill to travel, as well as saves patients time and money.Because of these benefits, the direct-to-patient model has increased clinical trial recruitment by up to 60 percent and helped to maintain patient retention by over 95 percent. Drug developers can also gain access to a larger patient population by onboarding those who are not located near participating hospitals or clinics.Patient centricity becomes more evident with the new generation of cell and gene therapies.From day one, CRYOPDP temperature-controlled logistics solutions have always been essential to improve and save patients lives. But, when speaking about cell and gene therapies in particular, this gains an even more significant meaning.The increase in personalised medicine, advanced therapies, and improved access to healthcare in the developing world are influencing future supply chain solutions development. Cell and gene therapies are enabling the healthcare community to shift the arrow and think about patients in a whole new way.Cell and gene therapies demand rigorous and precise temperature control to ensure that the therapies maintain their viability. And maintaining temperature control calls for flawless implementation and execution.From designing the best transportation route to selecting the correct packaging, every detail is critical to keep product integrity high under all conditions, and for this to happen, the healthcare community can count on CRYOPDP specialists who can meticulously handle the entire supply chain process. We've been supporting the life sciences and healthcare communities and focused on improving patient centricity with innovative temperature-controlled logistics solutions because thinking about the patient and the outcome of our work is what moves and inspires us to be better every day.

In all the geographies of the world that we cover, around 150 countries, we produce an operational performance of 99.96%. And to deliver such operational performance, we count on our employees, the specialists around the globe, to follow our quality standards and protocols in detail, so we can deliver a quality service.

When dealing with patients lives, there is no room for errors. Its all about quality of service making sure that lifesaving samples are distributed on time, within the correct specifications and at the right temperature to ensure the patient's health is never compromised.This commitment has helped CRYOPDP to win numerous industry awards, including Best Clinical Trial Logistics Provider in APAC at the Bioprocessing Excellence Awards 2021 and Most Advanced Healthcare Solution Providers from Europe 2021 by Healthcare Insights Magazine.Our achievements are being recognised across the industry, and as we continue to improve our services for healthcare communities, it will be the end patient that benefits the most.

See the rest here:
The Importance of Patient Centricity in Clinical Research and Cell / Gene Therapy Development - Contract Pharma

New York, July 13, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization (WHO), around 10 million deaths, or nearly 1 in 6 deaths, were caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. If found early and appropriately treated, many tumors (30% to 50%) are curable. According to the American Cancer Society (ACS), 1,918,030 new cancer cases and 609,360 cancer deaths are expected in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily in the United States.

In recent research titled Global Gene Therapy Market, Kenneth Research provided a brief overview of market elements including growth drivers, restraint factors, current market trends, and potential for future growth. The influence of COVID-19 and its effects on end-users are both thoroughly examined in the market research report, which covers the forecast period, i.e., 2022-2031. In addition, the research study examines the product portfolios and market expansion plans of the principal competitors.In 2020, according to the World Cancer Research Fund (WCRF), there were 18 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. The growth of the global gene therapy market can be attributed on account of the rising prevalence of cancer cases. Also, the adoption of gene therapies for the treatment of cancer is predicted to grow the market further. For instance, at the University of Pennsylvania, the first trial for testing a CRISPR-created cancer medicine was launched in the United States in 2019.CRISPR is a gene-editing-tool, that can modify any DNA segment within the 3 billion letters of the human genome. The global gene therapy market is expected to gather around USD 6 billion in revenue by 2031 and grow with a CAGR of ~34% over the forecast period. Get A Sample Copy of This Report @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. On the back of rapid rising cancer incidence rates, and the availability of high disposable income, the market in North America is predicted to experience significant expansion over the course of the forecast period. For instance, the Cancer Facts & Figures 2021 by the American Cancer Society, the study estimates that 1.9 million new instances of cancer were diagnosed and 608,570 cancer deaths in the United States in 2021. Also, an increase in the demand for gene-therapy-related R&D activities further helps the growth of the market. According to the World Bank Data, the domestic general government healthcare expenditure in the U.S. was 5,552.60 IN 2019 whereas in Canada the domestic general health care expenditure was 3,873.70 in 2019. Thus, a rise in government health care support is expected to expand the gene therapy-related R&D activities and further aid on to improve the market in the region.On the other hand, the global gene therapy market in the Asia Pacific region is anticipated to experience the greatest CAGR throughout the forecast period owing to the growing population in the region and increased approval and availability of gene therapy products. According to the World Bank data, the total population of China was 1.41 billion in 2020 whereas, India had 1.38 billion people in 2020. As the population grows, the likelihood of contracting a disease increases. Additionally, it is anticipated that increased government efforts to upgrade the health care infrastructure and rising healthcare costs in that region are expected to expand the industry. Also, the health care expenditure in Japan in 2019 was 10.74% whereas, in China, the GDP was 5.35%. In addition to that, the domestic general government health expenditure per capita for Japan was 3,846.54 in 2019 and China was 492.72 in 2019. Thus, growing health care expenditure and government support in health care expansion are further expected for the growth of the market in the region.

Browse to access In-depth research report on Gene Therapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/gene-therapy-market/10070542

The study further incorporates Y-O-Y Growth, demand & supply and forecasts future opportunities in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC[Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia Pacific(China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa(Israel, GCC[Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa).The global gene therapy market is segmented by indication into cancer, metabolic disorders, eye disorders, cardiovascular diseases, and others. Among that the cancer segment is predicted to hold the largest share over the forecast period. On account of the growing widespread presence of cancer cases, the growth of the market can be accredited. The estimated number of new cases of cancer patients in India was around 11,57,294 cases which had risen to 13,24,413 total cases in 2020. In addition to that, the total number of cancer patients was 1,708,921 in 2018 in the U.S., according to the Centers for Disease Control and Prevention (CDC) which got increased to an estimated rate of 1.8 million new cases in 2020. The statistical studies exhibit an increasingly widespread of the disease worldwide which is expected to drive the growth of the segment. Gene therapies are used to treat a variety of malignancies, including those of the brain, lung, breast, pancreatic, liver, prostate, bladder, head & neck, skin, and ovary. For instance, according to the World Cancer Research Fund (WCRF), the most common cancers around the world were breast and lung cancers, accounting to 12.5% and 12.2% respectively of all new cases that were expected to be diagnosed in 2020. Also, there were 1.9 million new instances of colorectal cancer, accounting for 10.7% of all cancer cases in 2020.

Get a Sample PDF of Global Gene Therapy Market @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented by end-user into pharma & biotech, and academia. Numerous ongoing researches and studies have been conducted in the pharma and biotech sector which is anticipated to account for the growth of the segment. For instance, based on a study by PhRMA, there were 289 gene therapies done in clinical development by biopharmaceutical companies in 2018 which had increased to 362 gene therapies in 2020. Also, 6 diseases were already being treated using gene therapy, whereas 362 cell and gene therapies were in the development stage in 2020. In addition to that, 9 cell or gene therapy products have been approved by U.S. Food and Drug Administration (FDA) as of February 2020; they are used to treat cancer, eye conditions, and uncommon inherited diseases.

The global gene therapy market is also segmented on the basis of technology and application.

Global Gene Therapy Market, Segmentation by Technology:

Global Gene Therapy Market, Segmentation by Application:

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070542

Some of the well-known leaders in the global gene therapy market that are included in our report are Kineta, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

Browse More Related Reports:

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinsons Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

View original post here:
Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031 - GlobeNewswire

Cergentis is a cornerstone acquisition that expands Solvias' solutions supporting complex and emerging therapies.

According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more researchers leverage emerging genetic engineering techniques to develop complex, novel medicines, they require sophisticated solutions to analyze their safety and effectiveness.

With the addition of Cergentis, Solvias supports the increasing number of global pharmaceutical, biotech, and contract development and manufacturing organizations developing genetically engineered therapies with an expanded platform of testing services highlighted by:

Archie Cullen, CEO, Solvias, stated:"We are relentlessly focused on ensuring the safety of new therapies in development. Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies. We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry."

Joris Schuurmans, CEO, Cergentis, added:"We are excited to become part of a global leader that complements our scientific expertise, innovation and customer service. Solvias and Cergentis share a deep commitment to providing our customers with the highest quality solutions and support to safely get their products into the hands of patients who need them."

Effective immediately, Mr. Schuurmans will join Solvias' leadership team and continue to lead operations for Cergentis.

Cergentis marks Solvias' second acquisition since partnering with health care investors Water Street Healthcare Partners and JLL Partners in 2020. The company has recruited industry leaders to join its board and commenced a program to significantly upgrade and expand its information technology platform and infrastructure to support its plans for global expansion.

Financial terms of the acquisition are not being disclosed. Achelous Partners served as the advisor to Cergentis on the transaction.

About CergentisCergentis is a trusted genomics-focused biotechnology company providing services and in-house solutions based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research institutes. With widely published and recognized genetic analyses, Cergentis supports a global customer base in the characterization and QC of genetically engineered models, biopharmaceutical cell line development, and cell- and gene therapy products. By helping to de-risk R&D program decisions, minimizing time-to-clinic, providing objective genomic evidence for regulators, and supporting patient safety, Cergentis aims to support biopharmaceutical medicine development programs worldwide. For more information, visit cergentis.com.

About Solvias AGSolvias is a worldwide leader in contract research, development and manufacturing for the pharmaceutical, biotech, material science and cosmetic industries. Drawing on 20 years of scientific excellence, the company provides flexible and scalable analytical and manufacturing solutions that ensure the integrity of pharmaceutical and medical device products across their life cycle. Headquartered in Kaiseraugst near Basel, Switzerland, Solvias and its laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. For more information, visit solvias.com.

SOURCE Solvias

Original post:
Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities - PR Newswire